TABLE 1-01 FINANCIAL HIGHLIGHTS
Years ended December 31
(All dollar amounts expressed in thousands of U.S. dollars, except per share data)


GLOSSARY
	Biovail
	Accelerated phase
	Opportunity
	Growth
	Innovation
	Progress
LETTER TO SHAREHOLDERS
REVIEW OF OPERATIONS
	Drug delivery technologies
	Product portfolio
	Product marketing
	Biovail Pharmaceuticals
	Biovail Pharmaceuticals Canada
	Strategic partnerships
	Product development
	ANDA product pipeline
	NDA product pipeline
	Contract research
	Manufacturing
PRODUCT PORTFOLIO
MANAGEMENT'S DISCUSSION & ANALYSIS
MANAGEMENT REPORT
AUDITORS' REPORT
CONSOLIDATED FINANCIAL STATEMENTS
	Consolidated Balance Sheets
	Consolidated Statements of Income (Loss)
	Consolidated Statements of Shareholders' Equity
	Consolidated Statements of Cash Flows
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEVEN YEAR FINANCIAL SUMMARY
SELECTED QUARTERLY DATA
BOARD OF DIRECTORS, OFFICERS
SHAREHOLDER INFORMATION

Biovail / bi'o-val 1. a fully integrated pharmaceutical company. 2. having expertise in controlled-release drug delivery technology. 3. a developer and marketer of novel medications for chronic diseases.

Biovail Corporation is a full-service pharmaceutical company that applies its proprietary drug delivery technologies in developing "oral controlled-release" products throughout North America. Biovail applies its proprietary drug delivery technologies to successful drug compounds that are free of patent protection to develop oral controlled-release pharmaceutical products. Branded oral controlled-release products improve on existing formulations, providing better therapeutic and economic benefits.

Biovail engages in the formulation, clinical testing, registration, manufacturing, sales and marketing of these oral controlled-release products throughout North America. To date, Biovail technologies have been used to develop 18 products that have been sold in more than 55 countries. Biovail's proven technologies are being applied to over 20 new products currently under development.

Biovail's scientists have gained a reputation for innovation and leadership in controlled-release drug delivery technology — a sector estimated at more than $8 billion in the U.S. alone. The Company has applied its expertise in this field to the development, and subsequent commercialization, of numerous pharmaceutical products that offer significant clinical advantages.

accelerated / ak-sel'e-rat. To increase the speed of. 2. To cause to occur sooner than expected.

THE TIME IT TAKES TO MOVE a promising compound from the laboratory to the doctor's office and pharmacy shelf is crucial in determining return on investment, bottom line results and, ultimately, the ongoing success of a pharmaceutical company.

Since its inception, Biovail has built a reputation not only for the diversity and innovation of its products, but also on the speed and efficiency of its development and approval processes. The Company's scientists, technicians, managers and others are all committed to the goal of accelerated commercialization, working closely with internal and independent researchers, government health regulatory agencies, such as the U.S. Food and Drug Administration, Therapeutic Product Directorate and others. The result is a productive pipeline that continues to bring innovative new products to the medical marketplace in a timely manner.

Biovail's record is exceptional. Its portfolio continues to expand, with more than 25 products currently being marketed directly or through strategic partnerships. In addition, exciting new products, including Cardizem® XL and FlashDose® fluoxetine, are scheduled to be commercialized in 2002.

Life moves fast. For people with chronic medical conditions, having quick access to new advanced medications can make the difference between joining in — and enjoying — the fast pace of everyday life, and watching from the sidelines. Innovative new products, such as Cardizem® XL, can help people live life to the fullest.

opportunity / op'er-too'ni-te 1. a) A favorable or advantageous circumstance or combination of circumstances. b) A favorable or suitable occasion or time. 2. A chance for progress or advancement.

BIOVAIL WAS BORN OUT OF OPPORTUNITY — the opportunity offered by the emerging field of controlled-release drug delivery technology. By realizing this potential, Biovail firmly established itself as a pioneer and leader in this dynamic area. Since then, an understanding of the changing needs of the medical marketplace and the ability to recognize and act on emerging opportunities have been hallmarks of Biovail's success. Through a combination of the development of novel delivery technologies, strategic acquisitions and focused drug development programs, the Company has been able to capitalize on new trends within the pharmaceutical industry.

The latest example is Biovail's entry into the highly promising new pharmaceutical science of chronotherapeutics with the development of Cardizem® XL. This exciting new approach to drug delivery could revolutionize the treatment of hypertension and many other common chronic disorders.

Seizing the opportunity is about more than just luck. It is about knowledge, preparation and expertise. Biovail's history — from the development of Tiazac®, to timely strategic acquisitions — has been marked by its ability to recognize and maximize emerging opportunities in the global pharmaceutical marketplace.

growth / groth 1. The act or process of expansion towards full development or maturity. 2. An increase in size, scope, strength or value.

ONE OF THE MOST EFFECTIVE WAYS to maximize opportunities in the marketplace is through a plan of strategic expansion that logically deploys resources when and where they are needed. Over the years, Biovail's expansion has been in keeping with its corporate objectives of integration and leadership in the controlled-release drug delivery sector.

The Company has expanded its scientific base by investing in research, as well as opportunistic technology acquisitions. Biovail continues to grow its product portfolio through internal development and in-licensing opportunities. It has expanded its manufacturing capabilities to meet increased demand through facility upgrades in Puerto Rico and Canada, as well as the acquisition of a new plant in Dorado.

Last year, Biovail made the next logical move towards its goals, with the addition of an established dynamic U.S. sales and marketing operation — Biovail Pharmaceuticals USA. Activities are already underway to dramatically expand this sales force by approximately 500 new representatives to maximize the potential of the Company's growing product line in the $200 billion U.S. pharmaceutical marketplace.

A body needs many elements to sustain strong, healthy growth. As a company matures, it must add the key resources and expertise it needs to achieve its objectives. The addition of a dynamic U.S. sales operation — Biovail Pharmaceuticals USA — is just one of the latest elements in Biovail's strategic growth.

innovation / in'e-va'shen 1. The act of introducing something new. 2. To bring in new methods, ideas, etc. 3. To introduce for the first time.

IN THE PHARMACEUTICAL INDUSTRY the word "innovative" can have two meanings. In the general sense, it can mean inventive, creative and the first to try something new. In industry jargon, it refers to a unique patented brand name drug developed and owned by an innovator company. Biovail can be called an innovative company in both senses.

On a general level, Biovail is a pioneer and innovator in controlled-release drug delivery. It has developed numerous proprietary technology platforms, including CEFORM®, Consurf, Enhanced Absorption, FlashDose®, and Shearform®, which can be applied to its own and in-licensed products. Products using Biovail's technologies have been first to market in a number of specialized drug delivery categories, and more are expected to follow in the near future.

Biovail is also a developer of innovative, or branded, drugs. Building on the success of its flagship proprietary product Tiazac®, the Company has targeted the higher-return branded product market. Its New Drug Application (NDA) pipeline is dedicated to the development of innovative branded products, to be marketed directly by Biovail Pharmaceuticals and select marketing partners.

True innovation means looking beyond the conventional. Just as jazz extended the boundaries of music, Biovail's scientists are changing the ways medications work through advanced new proprietary drug delivery technology platforms, such as FlashDose®, CEFORM®, and others.

progress / prog'res 1. Forward or onward movement towards a destination. 2. Advance or development towards betterment, completion, improvement, etc.

GROWTH OR MOVEMENT without direction is, in the long-run, self-defeating. By contrast, Biovail's growth is directed towards a clearly identified goal — to be one of the world's premier, fully-integrated pharmaceutical companies.

To achieve this goal, Biovail will continue to pursue a multi-faceted strategy that includes ongoing new product development and the maintenance of a strong NDA product pipeline. Biovail is engaged in the development and marketing of products in the therapeutic areas of cardiovascular, pain management and central nervous system (CNS) products, with emphasis on chronic care medications. Biovail will work to expand its sales force to maximize marketing opportunities in the U.S. and Canada. The Company will also work to develop synergistic marketing partnerships in North America and around the world. In addition, through Biovail Ventures, the Company will invest in strategic technology partnerships, early stage development companies and acquisitions that will strengthen its core operations.

Overall, Biovail will continue to emphasize sustainable growth, profitability and leadership within its industry sector through a strategy of steady and focused progress.

Progress involves steady movement towards a goal or objective, becoming better and more capable each step of the way. Biovail's progress over the past year has been significant, highlighted by a number of new product launches and a milestone agreement with GlaxoSmithKline that advances the Company's position within the global marketplace.

Biovail's performance in 2001 was highlighted by record revenues and earnings, growth of U.S. and Canadian sales operations, the continued development of a number of highly promising new products and a landmark bilateral licensing agreement.

The year 2001 was the most successful in the history of Biovail Corporation, and continued the trend of ongoing record growth established over the past few years.

The growth experienced by the Company in the past 12 months reflects the realization of two significant initiatives undertaken at the end of 2000; specifically the acquisition of the Cardizem® line of products and the entry into the U.S. sales and marketing arena. It also reflects the continuing maturation of Biovail's product line, and of the Company as a significant force within the North American pharmaceutical industry.

The addition of the market-leading Cardizem® family of products made an immediate positive impact on the Company, both in terms of direct revenue and enhanced positioning among North American health professionals. Sales of Cardizem® products were strong in the U.S. and Canada, adding over $160 million in incremental revenue during 2001. In addition, the inclusion of Cardizem® in the Biovail portfolio gave the Company a significantly stronger presence in the $4.5 billion U.S. calcium channel blocker market and enabled the Company to better leverage its sales force.

Overall product sales revenue increased by 139% in 2001 to a record level of $537.1 million. Performance was impressive across the portfolio: from Tiazac®, which increased its share of the once-daily diltiazem market to 24% through the efforts of Biovail's marketing partner Forest Laboratories, to the Company's line of bioequivalent (generic) products marketed in the U.S. under license by Teva Pharmaceuticals. Biovail's bioequivalent version of the anti-hypertensive medication Procardia® XL was added to Teva's portfolio during the year.

Biovail's new U.S. marketing division, Biovail Pharmaceuticals USA, also made a significant impact. With a line-up of branded products enhanced by the Cardizem® family, Biovail Pharmaceuticals USA exceeded sales expectations in its first year. Its presence in the U.S. market is destined to grow significantly. The Company is committed to a program of expansion of sales personnel and resources. Already underway, this expansion will add 500 professional sales representatives, providing better coverage of the U.S. health professional market.

These additional resources will allow Biovail to maximize the potential of its existing portfolio, as well as exciting new products to be launched in 2002 and the years to come.

Biovail's Canadian sales operations also had an exceptional year in 2001. Biovail Pharmaceuticals Canada (renamed from Crystaal as part of the Company's North American branding strategy) achieved record pull-through sales of $80 million driven by strong performances of Tiazac®, Cardizem® CD and Celexa®, among other products in its expanding portfolio. Biovail Pharmaceuticals Canada continues to be one the country's fastest growing drug companies, and is targeting even greater success in 2002.

Its efforts, along with those of Biovail Pharmaceuticals USA, will only be enhanced by the Company's growing reputation in the international pharmaceutical community. This reputation was further solidified in the fourth quarter with the announcement of an exciting licensing agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Biovail will license its novel controlled-release once daily formulation of bupropion hydrochloride (HCl) to be marketed worldwide by GSK for depression. Biovail will manufacture and supply the product to GSK, and will have the option to co-promote the product in the U.S. upon approval. Biovail also acquired the right to co-promote GSK's Wellbutrin® SR in the U.S. during 2002. In addition, the Company gains exclusive U.S. promotion and distribution rights to GSK's Zovirax® Ointment and Zovirax® Cream.

This landmark bilateral agreement with one of the world's leading multinational pharmaceutical companies is a validation of Biovail's drug delivery expertise and its position in the global marketplace.

Wellbutrin® and Zovirax® will add to a portfolio that will be further expanded in the coming months by a number of significant products. Perhaps the most exciting of these is Cardizem® XL, a significant advance in diltiazem products for the treatment of hypertension. Cardizem® XL is an innovative product, designed to work in synergy with the body's circadian rhythms. When taken at night, it delivers peak drug concentration during the early morning hours when a number of factors, including rising blood pressure, maximize the risk of adverse cardiac events, such as a stroke or heart attack. Highly promising clinical results for this unique product indicate that it should be a valuable resource in the clinician's fight against hypertension, a leading cause of heart disease. A New Drug Application (NDA) for Cardizem® XL was filed with the U.S. Food and Drug Administration in the third quarter of 2001 and approval is anticipated in 2002.

Along with Cardizem® XL, Biovail currently has more than 20 products under development. Many of these are in late stages of development. Among these are branded extended release formulations of tramadol, a treatment for moderate to severe pain, the anti-anxiety medication buspirone and several undisclosed products. The Company is also following up on the success of the application of its FlashDose® technology to Boots Pharmaceuticals' Nurofen Meltlets® ibuprofen product, by filing NDAs for two new FlashDose® products. These include FlashDose® formulations of the insomnia drug zolpidem (Ambien®) and the anti-depressant fluoxetine (Prozac®). FlashDose® is a proprietary oral drug delivery format that offers more flexible and convenient dosing as opposed to traditional pills and capsules.

Biovail continued to strengthen its other operating divisions throughout 2001. Initiatives in this area included the upgrading of the Contract Research Division's clinical facilities to allow for more advanced clinical trials, as well as the expansion of the Manitoba manufacturing operations to meet increasing demand. In addition, the new Dorado, Puerto Rico plant successfully completed several FDA inspections during the year and should be fully operational in 2002.

During the year, Biovail undertook a number of financial initiatives. These included the elimination of approximately $700 million in debt, and a successful equity offering in November that raised approximately $560 million.

In financial terms, 2001 was an exceptional year for Biovail, marked by another record performance. Total revenues for the 12 months ended December 31, 2001 were $583.3 million, an increase of 89% over 2000. Net income for 2001 increased by 64% to $202.9 million compared to $124 million for the previous year and diluted earnings per share increased 57% to $1.35 per share versus $0.86 per share in 2000, excluding certain charges.

As the New Year begins, Biovail Corporation is in an excellent position, with more products in its development pipeline than ever before, an expanding North American sales presence, a healthy financial structure and strong indicators for sustainable growth for the immediate and long-term future.

The significant achievements of the past year would not have been possible without the dedication of our employees and the confidence of our shareholders. On behalf of Senior Management and the Board of Directors, I would like to thank them for their continued support.

Biovail Corporation is a fully-integrated pharmaceutical company engaged in the development, manufacturing, sales and marketing of proprietary advanced controlled-release medications for the treatment of chronic medical conditions.

Biovail Corporation is an innovator and pioneer in the demanding discipline of controlled-release drug delivery technology. Since its inception, the Company has developed a number of proprietary drug delivery technology platforms. These have been applied to carefully selected drug compounds to produce once daily controlled-release products that offer significant therapeutic and competitive advantages.

Biovail maximizes competitive advantages through careful selection of its target drug compounds.

The therapeutic advantages, well documented and accepted by the international medical community, center on superior predictability and control of the delivery of the drug's active ingredients, leading to improved therapeutic efficacy and reduced side effects. These, in turn, lead to reduced dosing, better side effect profiles, improved compliance, superior outcomes and potential savings to the health care system.

Biovail maximizes competitive advantages through the careful selection of its target drug compounds, concentrating on successful products in high volume chronic categories. The Company has focused its efforts on the development of proprietary once daily versions of successful multiple daily dose products, as well as cost-effective bioequivalent versions of existing off-patent branded once daily medications.

At the core of Biovail's scientific capabilities are proprietary controlled-release drug delivery technology platforms. These platforms, which include CEFORM®, Consurf, Enhanced Absorption, FlashDose® and Shearform®, can be applied to a wide range of existing pharmaceutical products, as well as to compounds currently under development, both by Biovail and other pharmaceutical companies.

As one of the first companies to specialize in controlled-release drug delivery technology, Biovail has firmly established itself at the forefront of one of the global pharmaceutical industry's fastest growing and most promising sectors — a sector currently estimated to be over $8 billion in annual sales in the U.S. alone, with high growth predicted well into the future. The Company has continued to build on this area of expertise through scientific research and synergistic acquisitions.

The Company's high capacity manufacturing facilities ensure Biovail's ability to meet steadily increasing demand for its products in North America and global markets.

Biovail's diverse product portfolio currently includes more than 25 products. These products represent both NDA (branded) and ANDA (bioequivalent) medications. They are marketed in the U.S., Canada and more than 50 countries around the world. In 2001, the Company's portfolio grew significantly through the addition of a number of key products. Among the most significant of these was the Cardizem® family of anti-hypertensive, anti-angina products.

Acquired at the end of 2000 from Aventis Pharmaceuticals Inc., this line of market leading diltiazem products was a major contributor to the Company's increased sales. The flagship product in this line, Cardizem® CD, is the leading selling diltiazem in the U.S., accounting for more than 13 million prescriptions a year. Total sales for the line, which includes Cardizem®, Cardizem® CD, Cardizem® SR and injectable products, exceeded $160 million in 2001.

With the Cardizem® line and Tiazac®, the Company's pioneering once daily diltiazem product, Biovail has solidified its position as a leading player in the $4.5 billion U.S. calcium channel blocker market. A position it will enhance even further with the addition of exciting new products.

Another significant new product launched by Biovail in 2001 was a bioequivalent version of Procardia® XL, an anti-hypertensive, anti-angina product. In addition, the Company's nutraceutical division, Nutravail, successfully launched a chewable calcium tablet, marketed under WalMart's Spring Valley® Brand.

Total product sales achieved record levels in 2001, generating revenues of $537 million, an increase of 139% over 2000.

Biovail has established key strategic marketing and in-licensing agreements with many of the world's leading pharmaceutical companies, including Celgene, Teva Pharmaceuticals and GSK.

Biovail's products are marketed in two distinct ways: through Biovail's own U.S. and Canadian sales operations and through strategic marketing partnerships with leading pharmaceutical companies.

The Company's strategic marketing partners currently include Forest Laboratories, Inc. and Teva Pharmaceuticals. Forest Laboratories currently markets Tiazac® in the U.S. and continues to expand the product's share of the once-daily diltiazem market, which exceeded 24% by the end of 2001.

Biovail's bioequivalent product portfolio is marketed in the U.S. by Teva Pharmaceuticals. These products also showed significant sales growth during the past year.

In addition, the Company has strategic marketing agreements for its products with 25 pharmaceutical companies serving Europe, Asia and other world markets.

The integration of DJ Pharma, a successful U.S. pharmaceutical sales and marketing operation acquired by the Company at the end of 2000, was completed in the first quarter of the year. The new division, Biovail Pharmaceuticals USA, provides the Company with a fully established U.S. marketing operation, along with additional revenue streams from existing in-licensed products.

Biovail Pharmaceutical USA's portfolio was enhanced by the addition of the Cardizem® line and additional Biovail products. The division performed extremely well during its first year, exceeding sales expectations. Revenue from sales generated by Biovail Pharmaceuticals USA during 2001 increased in excess of 50%.

The Company's objective is to continue to build Biovail Pharmaceuticals USA through the strategic addition of the sales resources required to optimize the significant opportunities represented by the $200 billion U.S. pharmaceutical market, the world's largest. In 2001, Biovail Pharmaceuticals USA expanded its sales force to over 300. Initiatives are currently underway to hire 500 additional sales representatives in 2002.

Crystaal Corporation, the Company's Canadian sales division markets a select portfolio of products, including Tiazac®, Retavase®, Celexa® and the newly added Cardizem® line.

In keeping with the Company's international branding strategy, the name of this division was changed to Biovail Pharmaceuticals Canada towards the end of 2001.

The division continued to build on the breakthrough success of 2000. Total pull-through sales increased over 60%, reaching in excess of $80 million in 2001, moving Biovail Pharmaceuticals Canada closer to its stated target of $200 million in sales by the end of 2005. Key success stories included increased sales of Tiazac®, Cardizem® CD and Celexa®, which has already achieved a market share of 14% and continues to be the fastest growing anti-depressant in the Canadian market.

Biovail Pharmaceuticals Canada is paralleling Celexa's success, and is one of the fastest growing pharmaceutical marketing companies in Canada.

Biovail Pharmaceutical's expanding sales team promotes the Company's impressive portfolio of products to health professionals in the U.S. and Canada.

Another significant source of revenue for Biovail is the licensing of products and drug delivery technologies to select international pharmaceutical partners. One example of this technology licensing is Nurofen Meltlets®, an innovative ibuprofen product marketed in the UK and Australia by Boots Healthcare International. The application of Biovail's proprietary FlashDose® technology allows Nurofen Meltlets® to 'melt in the mouth', enabling it to be taken anywhere, without water. Biovail expects to apply this technology to exciting market opportunities, either alone or in collaboration with strategic partners.

In 2001, Biovail took a major step forward in terms of strategic partnerships with the completion of a major multi-faceted reciprocal licensing agreement with GlaxoSmithKline (GSK), one of the world's largest and most respected pharmaceutical companies.

Under the terms of this milestone agreement, the Company licensed worldwide marketing rights to GSK for its novel once-daily controlled-release formulation of bupropion HCl, a successful treatment for depression. Bupropion is currently marketed by GSK in multiple dose formulations under the Wellbutrin® (for depression) and Zyban® (for smoking cessation) brands. The agreement also provides for Biovail to manufacture and supply the new product, Wellbutrin® Once Daily, to GSK, along with an option to co-promote the new product in the U.S. Biovail and GSK expect to file a New Drug Application (NDA) for Wellbutrin® Once Daily with the U.S. Food and Drug Administration in mid 2002.

Biovail will also co-promote GSK's currently marketed twice-daily Wellbutrin® SR product in the U.S. during 2002. U.S. sales of Wellbutrin® SR were in excess of $1 billion in 2001.

In addition, Biovail obtains the rights to exclusively promote and distribute GSK's topical anti-viral products Zovirax® Ointment and Zovirax® Cream (on approval) in the U.S.

Future success and sustainable growth is ensured by the number, diversity and market potential of the products in Biovail's R&D pipeline.

Biovail's strategy to future success and sustainable growth continues to be built upon the number, diversity and market potential of the products in its research and development pipeline. With state-of-the-art R&D facilities in the U.S., Canada and Ireland and a dedicated staff of leading experts in controlled-release drug delivery technology, the Company is well positioned to build on its leadership in this area.

Ongoing research and development is devoted to NDA products to expand the Company's therapeutic focus in the management of pain, cardiovascular and central nervous system (CNS) conditions. In total, the Company has over 20 promising products in development.

The past year was particularly productive for Biovail's bioequivalent product pipeline, with a number of compounds progressing towards commercialization. Final FDA approval was received for the Company's bioequivalent version of the $130 million anti-hypertensive, anti-angina medication Procardia® XL 30mg. The product was subsequently launched by Biovail's marketing partner, Teva Pharmaceuticals.

Abbreviated New Drug Applications were filed for bioequivalent versions of Adalat® CC 90mg, Procardia® XL 90mg and Tegretol® 400mg. Approval of these products is expected by the end of 2002.

Going forward, Biovail's development activities will be more focused on NDA opportunities.

The Company also maintains a productive pipeline of NDA, or branded, compounds. Research in this area is focused on the development of formulations that offer therapeutic advantages over the existing drug as well as the higher profitability of branded products.

One of the most significant new branded products currently under development is the anti-hypertensive, anti-angina medication Cardizem® XL. This is the first once daily graded release diltiazem product to time the release of its active ingredient to match the human body's internal clock, or circadian rhythms. When taken at night, Cardizem® XL delivers its peak concentration in the early waking hours when, due to rising blood pressure and other factors, the greatest risk of stroke or heart attack exists. Phase III clinical trials of Cardizem® XL taken at night have been extremely positive, demonstrating a significant reduction in diastolic and systolic blood pressure between 4 am and noon. As a result of these studies, Biovail filed an NDA for Cardizem® XL with the U.S. FDA during the third quarter of 2001.

Positive Phase III results were also recorded for the Company's extended-release formulation of tramadol, a leading product for the treatment of moderate to moderately severe pain syndromes. At present, tramadol is only available in a multi-dose formulation. Marketed as Ultram®, this formulation recorded growth of 19% in 2001, with U.S. sales exceeding $662 million.

Additionally, New Drug Applications were filed with the U.S. FDA for two FlashDose® products in 2001. In October, an NDA was filed for a FlashDose® version of the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Marketed as Prozac® for the treatment of depression, obsessive-compulsive disorder and bulimia, fluoxetine registered annual sales in excess of $2.8 billion in 2001. At the end of the year, an NDA was filed for a

FlashDose® formulation of zolpidem, a treatment for insomnia with yearly brand sales of approximately $997 million.

Also in 2001, Biovail filed a New Drug Submission in Canada for Celgene Corporations' chirally pure version of d-methylphenidate (d-MPH), a novel formulation for the treatment of attention deficit hyperactivity disorder. On approval, Biovail will have exclusive Canadian marketing rights for this product.

The Company's independent Contract Research Division (CRD) provides Biovail and the international biopharmaceutical industry with specialized contract research services focused on early clinical trials and bioanalysis.

A significant expansion of the main facility was completed in the first quarter, including the addition of laboratory space, the redesign and 7,500 square-foot expansion of the clinic areas, and the creation of a state-of-the-art Phase I clinic. The expansion was undertaken to better support the conduct of early clinical trials and bioanalysis for Biovail and independent clients.

With a brand new 12 hospital bed Phase I clinic, and equipped with a sophisticated telemetry monitoring system, CRD can now accommodate Phase I and Phase II trials with stringent subject-safety monitoring parameters, allowing it to take advantage of the recent Canadian regulatory changes supporting Phase I clinical trials in Canada. The first Phase I clinical trial was conducted by CRD in the fourth quarter of 2001.

Biovail currently operates three modern manufacturing facilities in Carolina and Dorado, Puerto Rico and Manitoba, Canada. The Manitoba facility will undergo a 40,000 square foot expansion in 2002.

Biovail's newest manufacturing facility, a 120,000 square foot cGMP pharmaceutical manufacturing plant in Dorado, Puerto Rico, received FDA approval for its QC operations in the third quarter of 2001 and is expected to receive packaging approval in 2002. The Dorado facility is capable of producing 15 billion units a year without expansion. In addition, the Company also operates a 23,000 square foot manufacturing facility in Carolina, Puerto Rico and a modern 105,000 square foot plant in Manitoba, Canada, which will be expanded by 40,000 square feet during 2002.

These state-of-the-art manufacturing facilities provide Biovail with the capacity to meet the anticipated increased demand for its own expanding product line, as well as in-licensed products for years to come.

PRODUCT		INDICATION	PARTNER STATUS	CURRENT STATUS
I. Pipeline Products
BRANDED (NDA)
Buspirone	1	Anxiety, Depression	Not Partnered	Phase III
Bupropion	1	Depression, Smoking Cessation	GlaxoSmithKline	Under Development
Metformin	1	Diabetes	Not Partnered	Under Development
Tramadol	1	Chronic Pain	Not Partnered	Phase III
Cardizem® XL	1	Hypertension/Angina	Not Partnered	Regulatory Review
Zovirax® Cream	5	Herpes	GlaxoSmithKline	Regulatory Review
Attenade®	3,8	Attention Deficit-Hyperactivity Disorder	Celgene Corporation	Under Development
Ampligen®	3,8	Chronic Fatigue Syndrome	Hemispherx Biopharma, Inc.	Under Development
Fibrostat®	3,8	Surgical Scars and Burns	Procyon BioPharma Inc.	Under Development
Citalopram CR		Depression	H. Lundbeck A/S	Under Development
5 FU	3	Cancer	Ethypharm S.A.	Phase IIb
5 Undisclosed	3	Pain Management/Anti-Viral	Ethypharm S.A.	Under Development
Corlopam	3,8	Hypertension	Elan Corporation plc.	Under Development
FlashDose® fluoxetine		Depression	Not Partnered	Regulatory Review
FlashDose® zolpidem		Sleeping Disorders	Not Partnered	Regulatory Review
FlashDose® paroxetine		Depression, other	Not Partnered	Under Development
FlashDose®^{[nc_sp,\t\][nc_cad,228][nc_so,\t\]}5 Undisclosed		Various	Not Partnered	Under Development
BIOEQUIVALENT (ANDA)
Dilacor XR	1	Hypertension/Angina	Teva Pharmaceuticals USA Inc.	Regulatory Review
Tegretol	1	Epilepsy	Not Partnered	Regulatory Review
II. In Market Portfolio
BRANDED (NDA)
Biovail Pharmaceuticals USA
Cardizem®	7	Hypertension/Angina	N/A	Commercialized
Zovirax® Ointment	3,5	Herpes	GlaxoSmithKline	Commercialized
Wellbutrin SR	9	Depression	GlaxoSmithKline	Commercialized
Teveten®	6	Hypertension	Solvay Pharmaceuticals	Commercialized
Teveten® HCT	6	Hypertension	Solvay Pharmaceuticals	Approved
Cedax®	3	Respiratory Infections	Schering-Plough Corporation	Commercialized
Rondec®	3	Respiratory/Allergy	Abbott Laboratories	Commercialized
Biovail Pharmaceuticals Canada
Cardizem®	7	Hypertension, Angina	N/A	Commercialized
Tiazac®	1,2	Hypertension, Angina	N/A	Commercialized
Retavase®	3	Acute Myocardial Infarction	Centacor, Inc. (division of J&J)	Commercialized
Celexa®	4	Depression	H. Lundbeck A/S	Commercialized
Monocor®	3	Hypertension, "C.H.F."	Wyeth Ayerst Canada Inc.	Commercialized
BIOEQUIVALENT (ANDA)
Trental	1	Peripheral Vascular Disease	Teva Pharmaceuticals USA Inc.	Commercialized
Cardizem® CD	1	Hypertension/Angina	Teva Pharmaceuticals USA Inc.	Commercialized
Verelan	1,3	Hypertension/Angina	Teva Pharmaceuticals USA Inc.	Commercialized
Voltaren XR	1	Arthritis	Teva Pharmaceuticals USA Inc.	Commercialized
Adalat CC	1,3	Hypertension/Angina	Teva Pharmaceuticals USA Inc.	Commercialized
Procardia XL	1	Hypertension/Angina	Teva Pharmaceuticals USA Inc.	Commercialized

N.B. Biovail has also developed 11 additional products that have been successfully commercialized by various licensee in numerous world markets.

Biovail's 2001 financial performance was highlighted by record revenues and earnings as it continued to evolve into one of the world's premier advanced drug delivery pharmaceutical companies

In 2001, we experienced continued financial growth and made significant progress in the development of highly promising new medications. This performance is indicative of our ongoing evolution into a leading marketer and developer of pharmaceutical products utilizing advanced proprietary drug delivery technologies.

Our results reflected the impact of the strategic business acquisitions completed during 2000, and the rapid integration of these acquisitions into our existing organization in 2001 with the goal to maximize their contribution. Most notably the increase in our revenue reflected the addition of the Cardizem® product line ("Cardizem®"), which we acquired from Aventis Pharmaceuticals Inc. ("Aventis"), and DJ Pharma, Inc.'s ("DJ Pharma") portfolio of products acquired in October 2000. Cardizem® is being marketed in Canada through Biovail Pharmaceuticals Canada ("BPC"), formerly known as Crystaal, and in the United States through Biovail Pharmaceuticals, Inc. ("BPI"), formerly known as DJ Pharma.

Our efforts in clinical programs and product development resulted in the filing of New Drug Applications ("NDA") for approval by the U.S. Food and Drug Administration ("FDA") for Cardizem® XL, a graded-release formulation of diltiazem, designed for night-time dosing, and FlashDose® formulations of the anti-depressant fluoxetine and the insomnia medication zolpidem. We also filed three Abbreviated New Drug Applications ("ANDA") for approval by the FDA for generic versions of Adalat CC 90mg, Procardia XL 90mg, and Tegretol 400mg. In Canada, we filed New Drug Submissions for the full range of dosage strengths for Cardizem® XL with the Therapeutic Products Directorate ("TPD").

The most significant event in 2001 in terms of business strategy was the conclusion of a multi-faceted agreement with GlaxoSmithKline plc ("GSK"). This agreement encompasses the collaborated final development and co-promotion of our novel controlled-release, once-daily formulation of bupropion hydrochloride ("HCl"), the co-promotion of Wellbutrin SR, GSK's existing sustained-release, twice-daily formulation of bupropion HCl, and the acquisition of the exclusive promotion and distribution rights to GSK's Zovirax topical products in the United States and Puerto Rico.

As we begin 2002, we believe we are financially well positioned to execute our growth strategies following the syndication of our $400 million revolving term credit facility in June 2001, and the successful public offerings in November 2001 of common shares for proceeds of $587.5 million and in March 2002 of 7⁷/8% Senior Subordinated Notes due on April 1, 2010 (the "Notes") for proceeds of $397.1 million. We also converted $300.0 million of our 6.75% Convertible Subordinated Preferred Equivalent Debentures (the "Debentures") into common shares, which significantly increased our equity base.

We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"), applied on a consistent basis. Our critical accounting policies include the use of estimates, product returns, rebates and allowances and their impact on revenue recognition, the recording of research and development expenses, the useful lives of goodwill and intangible assets, and the realizability of deferred tax assets.

In preparing our consolidated financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Our actual results could differ from these estimates. Significant estimates made by us include the calculation of reserves for uncollectible accounts, product returns, rebates and allowances, useful lives of long-lived assets, including intangibles, and the realizability of deferred tax assets.

We recognize product sales revenue when the product is shipped to the customer provided we have not retained any significant risks of ownership or future obligations with respect to the product shipped. Revenue from product sales is recognized net of provisions for product recalls, returns, rebates and allowances. These provisions are established in the same period as the related product sales are recorded and are based on estimates of the proportion of product sales subject to recall, return, rebate or allowance. A significant change in these estimates could have a material impact on our results of operations.

We expense research and development costs in the period in which they are incurred. We write-off acquired research and development having no alternative future use at the time of acquisition. The cost of intangibles that we purchase from others for a particular research and development project that have no alternative future use are written-off at the time of acquisition. We may pursue product or business acquisitions that could result in a charge for research and development costs acquired, which could have a material impact on our results of operations.

Our goodwill and intangible assets are stated at cost, less accumulated amortization computed using the straight-line method based on their estimated useful lives ranging from six to twenty years. Useful life is the period over which the item of goodwill and intangible assets is expected to contribute directly or indirectly to our future cash flows. We determine useful lives for goodwill and intangible assets based on a number of factors such as legal, regulatory or contractual limitations, known technological advances, anticipated demand and the existence or absence of competition. A significant change in these factors may warrant a revision of the expected remaining useful life of an item of goodwill and intangible assets resulting in accelerated amortization or an impairment charge, which could have a material impact on our results of operations. Effective with the adoption of the Financial Accounting Standards Board's ("FASB") Statement of Financial Accounting Standard ("SFAS") No. 142, "Goodwill and Other Intangible Assets", on January 1, 2002, goodwill and certain other of our intangible assets will no longer be amortized but will be subject to annual impairment tests (see Recent accounting pronouncements).

We have recorded a valuation allowance on deferred tax assets primarily related to operating losses and tax credit carryforwards. We have assumed that these carryforwards are more likely than not to be unrealized based on estimated future taxable income and tax planning strategies in the related jurisdictions. The implementation of tax planning strategies or a change in the outlook for future taxable income in these jurisdictions could result in the recognition of some portion or all of these carryforwards, which could result in a material increase in our results of operations through the recovery of deferred income taxes.

Effective January 1, 2001, we implemented the FASB's SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities". SFAS No. 133 requires a company to recognize all derivative instruments as assets or liabilities in its balance sheet and to measure them at fair value. The adoption of SFAS No. 133 did not result in any cumulative effect adjustment in our consolidated statements of income (loss), and did not have a material impact on our financial position or results of operations as we do not use derivative financial instruments or engage in hedging activities.

On October 26, 2001, we entered into a development and co-promotion agreement with GSK for bupropion HCl. Under the terms of the agreement, we licensed to GSK a novel controlled-release, once-daily formulation of bupropion HCl ("Wellbutrin Once Daily") for sales and distribution on a worldwide basis excluding Canada. Bupropion HCl, which is marketed by GSK for the treatment of depression as Wellbutrin and for smoking cessation as Zyban, is currently sold in sustained-release ("SR"), twice daily, and immediate-release, four-times daily, dosage formats. Under the terms of the Wellbutrin Once Daily agreement, we will collaborate with GSK to direct regulatory and scientific development to seek regulatory approval of Wellbutrin Once Daily. Together with GSK, we intend to file a NDA for Wellbutrin Once Daily with the FDA during mid-2002. When and if FDA approval is received, we will manufacture and supply Wellbutrin Once Daily to GSK for a share of the revenue generated by future sales of Wellbutrin Once Daily. Together with GSK, we will co-promote Wellbutrin SR and we will have the option to co-promote Wellbutrin Once Daily when and if FDA approval is received in the United States.

Effective January 1, 2002, we acquired from GSK the exclusive distribution rights for prescription strength Zovirax Ointment and, upon FDA approval, Zovirax Cream for the United States and Puerto Rico. Zovirax is indicated for the treatment of herpes. We paid GSK $133 million on January 2, 2002 for the distribution rights to the Zovirax products until December 31, 2011. In the event of the termination of the Wellbutrin Once Daily development agreement by either party, we would be required to pay GSK additional payments of $22 million per year for calendar years 2002 through 2006, with an aggregative cumulative total of all additional rights payments not to exceed $99 million, and for calendar years 2007 through 2011 we would be required to pay GSK additional payments based upon a percentage of our gross sales of the Zovirax products during the immediately preceding calendar year.

GSK will manufacture and supply Zovirax Ointment, and Zovirax Cream upon FDA approval, to us. We began promotional efforts related to Zovirax Ointment in January 2002 and we intend to launch Zovirax Cream when and if FDA approval is received. In order to gain FDA approval for Zovirax Cream, GSK will work with the FDA to reinstate an NDA previously filed by GSK for the product. GSK will also conduct a pediatric Phase IV marketing study for Zovirax Cream.

On January 4, 2002, we invested approximately $2.5 million in non-voting, non-participating preferred shares of Procyon Biopharma Inc. ("Procyon"), and acquired the exclusive marketing rights to FIBROSTAT in the United States. FIBROSTAT is a topical therapeutic for scar management. We will pay aggregate fees of approximately $5.1 million to Procyon for the development of FIBROSTAT, subject to the attainment of certain milestones. We will pay Procyon a licensing fee of approximately $3.1 million and royalties upon approval and commercialization of FIBROSTAT in the United States.

On March 18, 2002, we announced that we had acquired from Solvay Pharmaceuticals Marketing and Licensing AG ("Solvay") the exclusive marketing rights for Teveten and Teveten HCT in the United States. Teveten is an angiotensin-II receptor blocker (ARB) and Teveten HCT is a combination formulation containing hydrochloroth-iazide (collectively "Teveten"). Teveten is prescribed for the treatment of hypertension and is indicated for use either alone or in conjunction with other anti-hypertensive medications. The purchase price for

Teveten was $94 million in cash and we will pay royalties to Solvay based upon a percentage of the net sales of Teveten in the United States. Under the terms of the agreement, Solvay will manufacture and supply Teveten to us, and will assist us in qualifying a site to enable us to manufacture Teveten for distribution in the United States. Solvay will pay us a marketing allowance, of $2,500,000 per quarter for each calendar quarter during 2002 and 2003, to compensate us for the re-launch and marketing of Teveten in the United States.

On April 15, 2002, we announced that we have entered into multiple agreements with Ethypharm S.A. ("Ethypharm") whereby we have acquired a 15% equity interest in Ethypharm and the right to license six ongoing product development programs for marketing in North America. We have also entered into a cross-license agreement with Ethypharm whereby we grant to each other non-exclusive licenses to use our CEFORM® technology and Ethypharm's Flashtab technology, respectively, relating to the development of new rapid dissolve pharmaceutical products.

We invested approximately $65 million to acquire 15% of the issued and outstanding shares of Ethypharm. We have an option to purchase up to an additional 5% interest in Ethypharm at the same price for a specified period and another 5% interest over a three-year period at predetermined prices. This strategic investment will help finance Ethypharm's growth strategies and gives us access to complementary drug delivery technologies, a strong intellectual property position and access to the pipeline products, several of which are in late stages of development.

We have licensed the marketing rights to six products from Ethypharm for commercialization in North America. Ethypharm is entitled to receive up to $61 million in milestone payments upon regulatory approval of the products within the territories as well as royalties on the net sales of the products. Ethypharm is committed to accelerate the developmental activities of the six licensed products through completion of Phase III clinical trials and to support the technology transfer required to allow us to efficiently and economically optimize the use of the Ethypharm technology in the manufacture and marketing of each product.

On December 29, 2000, we completed the acquisition of Intelligent Polymers Limited ("Intelligent Polymers") for total consideration of $204.9 million. Intelligent Polymers was formed in July 1997 to fund the development of once-daily, controlled-release branded generic products for chronic disease states, such as anxiety, depression, pain management, and diabetes. Prior to September 29, 2000, we were developing the products on behalf of Intelligent Polymers pursuant to a development and license agreement.

In 2000, as a result of the acquisition of Intelligent Polymers we recorded a charge for acquired research and development of $208.4 million, as required under GAAP. At the date of acquisition, the products under development were in various stages of completion, had not reached technological feasibility, and had no known alternative uses other than for the therapeutic indications for which they were being developed. At the date of acquisition, none of the products had been submitted for approval with the FDA. Since pharmaceutical products cannot be marketed without regulatory approvals, we will not receive any benefits from the products unless regulatory approval is obtained.

We are continuing the development programs for the various products previously being developed for Intelligent Polymers. Two of these developmental programs are now in Phase III clinical trials (tramadol and buspirone), and another (bupropion) has been licensed to GSK.

In December 1999, we had exercised our option to acquire from Intelligent Polymers the rights to the generic version of Procardia XL, which we had developed on their behalf, for $25 million. As required under GAAP, the right to Procardia XL was written-off as acquired research and development in 1999 since at the time of acquisition the product had not received regulatory approval from the FDA, and had no known alternative future use.

On December 28, 2000, we acquired the North American rights to Cardizem® from Aventis. Cardizem® is a leading calcium channel blocker prescribed for the treatment of hypertension and angina. We paid Aventis total consideration of $409.5 million, of which $239.5 million was paid at closing. The remaining $170 million was paid equally over the four quarters of 2001, and was appropriately discounted for valuation purposes. We intend to capitalize on the competitive advantage of the Cardizem® brand name by attaching it to our improved once-daily diltiazem product, Cardizem® XL.

On October 6, 2000, we acquired DJ Pharma, a pharmaceutical sales and marketing company with approximately 300 sales representatives located in the United States. The purchase price was $165.1 million including costs of acquisition, plus the assumption of $34.2 million of debt. We accounted for the acquisition of DJ Pharma under the purchase method. The assets, liabilities, revenue and expenses of DJ Pharma have been included in our consolidated financial statements since the date of acquisition.

As a result of this acquisition, we obtained the rights to DJ Pharma's portfolio of products, as well as a trained workforce and infrastructure. The acquisition of DJ Pharma was significant to our strategy of becoming a fully integrated pharmaceutical company because, prior to the acquisition of DJ Pharma, we had no direct access to the United States market and were reliant on our marketing partners. The acquisition of DJ Pharma dramatically enhances the value of our product pipeline through our ability to now market directly to physicians, and provides an infrastructure upon which we intend to grow to meet our increasing portfolio of products.

On November 12, 1999, we acquired Fuisz Technologies Ltd. ("Fuisz") in order to expand our available drug delivery technologies to include taste masking, rapid dissolve and enhanced absorption, which we are applying in the development of FlashDose® versions of several oral dosage, controlled-release branded products. The total consideration paid for Fuisz consisted of $75.6 million in cash and common shares valued at $88.2 million. In addition, we incurred costs related to the acquisition of $7.3 million in 1999, and an additional $17.2 million in 2000. We accounted for the acquisition of Fuisz as a step acquisition under the purchase method of accounting. Certain operations of Fuisz were not considered strategic to our business plans, and accordingly were sold. We did not recognize any gain or loss on those transactions, because those operations were included at fair value in the purchase price allocation on November 12, 1999.

In our 1999 consolidated financial statements, we recognized a $58.4 million equity loss reflecting our 49% interest in the results of Fuisz for the period from September 4, 1999, the date we acquired significant influence, to November 12, 1999, the date we acquired control, which included a $56.8 million charge for acquired research and development. The assets, liabilities, revenue and expenses of Fuisz have been included in our consolidated financial statements since November 12, 1999.

Under GAAP, the acquisition of Fuisz resulted in a total charge of $137.5 million for acquired research and development. At the date of acquisition, the products under development were in various stages of completion, had not reached technological feasibility, and had no known alternative uses other than for the therapeutic indications for which they were being developed. At the date of acquisition, none of the products had received regulatory approval. Since pharmaceutical products cannot be marketed without regulatory approvals, we would not receive any benefits from the products unless regulatory approval was obtained.

In 2000, one of the products under development at the acquisition date received approvals for marketing in the United Kingdom and Australia. The product, a FlashDose® form of ibuprofen, represented the first commercial introduction of a product utilizing the Fuisz drug delivery technology. Subsequently, we terminated substantially all of the developmental projects Fuisz had been working on and re-directed the developmental efforts to formulating a specific number of FlashDose® products targeting our therapeutic areas of focus. These new programs utilize some or all of the Fuisz drug delivery technologies.

Total revenue in 2001 was $583.3 million, an increase of $274.1 million or 89% from $309.2 million in 2000, which was $136.7 million or 79% higher than 1999 total revenue of $172.5 million. Net income in 2001 was $87.4 million, or diluted earnings per share of $0.58, compared to net losses in 2000 and 1999 of $148.0 million and $110.0 million, or diluted losses per share of $1.16 and $1.07, respectively.

We utilize a measure of net income and diluted earnings per share on a basis that excludes certain charges. This measure is a non-GAAP measure that does not have a standardized meaning and, as such, is not necessarily comparable to similarly titled measures presented by other companies. We have consistently applied this measure when discussing earnings or earnings guidance and will continue to do so going forward. This measure is provided to assist our investors in assessing our operating performance. We believe that most of our investors prefer to analyze our results based on this measure as it is consistent with industry practice. The charges were excluded because they were considered to be of a non-operational nature in the applicable year. The excluded charges are also disclosed to give investors the ability to further analyze our results. Investors should consider this non-GAAP measure in the context of our U.S. GAAP results. The following table reconciles, for each year indicated, our net income (loss) in accordance with U.S. GAAP to our net income excluding certain charges, and displays our diluted earnings per share excluding certain charges.

Net income excluding certain charges was $202.9 million, $124.0 million and $52.2 million in 2001, 2000 and 1999, respectively. Diluted earnings per share excluding certain charges were $1.35, $0.86 and $0.48 in 2001, 2000 and 1999, respectively. Net income and diluted earnings per share excluding certain charges increased by 64% and 57%, respectively for 2001 compared to 2000, and by 138% and 79%, respectively for 2000 compared to 1999. For 2001, the charges excluded consist of a write-down of assets of $80.5 million primarily related to the Keftab and Dura-Vent product rights, and debt conversion premiums of $34.9 million related to the surrender and redemption of our Debentures. For 2000, the charges excluded consist of $208.4 million for acquired research and development, arising from the acquisition of Intelligent Polymers, $20.0 million for the premium paid to extinguish our 10⁷/8% U.S. Dollar Senior Notes (the "Senior Notes"), and $43.5 million for the cumulative effect of the adoption of the U.S. Securities and Exchange Commission's ("SEC") Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" ("SAB 101"). For 1999, the charges excluded consist of $105.7 million for acquired research and development, arising from the acquisition of Fuisz and the purchase of Procardia XL from Intelligent Polymers, an equity loss in Fuisz of $58.4 million, and a net gain on the disposal of long-term investments of $1.9 million.

Our revenue is derived from sales of pharmaceutical products, the co-promotion of pharmaceutical products, providing research and development services, and from royalties and license fees. Product sales include sales of products developed and manufactured by us for our licensees and direct marketing in Canada and the United States of proprietary and in-licensed products. Research and development revenue relates to product development activity on behalf of third parties, and pharmaceutical contract research services. Royalties primarily arise on sales of the products we developed. License fees are derived from the license of our technologies or product rights.

The following table displays, for each year indicated, the percentage of each source of revenue to total revenue, and the percentage change in the dollar amount of each source and the total as compared to the prior year.

In 2001, product sales were $537.1 million, compared to $225.0 million in 2000 and $99.5 million in 1999.

Product sales comprised 92% of total revenue in 2001, compared to 72% in 2000 and 58% in 1999.

Product sales increased by 139% in 2001 compared to 2000 primarily due to the addition of Cardizem® and DJ Pharma's product portfolio. Excluding Cardizem® and DJ Pharma's product portfolio, we experienced organic revenue growth from product sales in excess of 50%. This growth primarily came from a higher contribution from generic products, reflecting the 2001 launch of Procardia XL 30mg, and the late 2000 launches of Procardia XL 60mg and Adalat CC 60mg. Our generic products are sold through our marketing partner, Teva Pharmaceuticals USA, Inc ("Teva"). In total, sales of our generic products in 2001 were nearly double those in

2000, and represented approximately 30% of product sales in 2001 compared to approximately 40% in 2000. Sales of Tiazac® increased by approximately 10% in 2001 compared to 2000, but declined as a percentage of product sales to approximately 20% in 2001 compared to approximately 40% in 2000.

Our product sales and gross margins for 2001 were adversely impacted by lost sales and costs associated with the voluntary recall of Keftab tablets, which was initiated by Eli Lilly & Company ("Eli Lilly") on March 7, 2001, because of undefined problems Eli Lilly had with the product's stability. Eli Lilly manufactured and supplied the product to BPI for marketing in the United States.

Product sales increased by 126% in 2000 compared to 1999 due to the combination of further market penetration of Tiazac®, several successful generic product launches, and the incremental revenues from DJ Pharma's product portfolio. Excluding DJ Pharma's product portfolio, we experienced organic growth from product sales in excess of 90%. The growth in our generic product sales was primarily from a combination of products launched in 1999, including Cardizem® CD, Trental and Verelan, and the early 2000 launches of Voltaren XR and Adalat CC 30mg ("Adalat"). Sales of Tiazac® increased by approximately 20% in 2000 compared to 1999, and sales of generic products increased by approximately 250% in 2000 compared to 1999.

Research and development revenue was $14.6 million in 2001, compared to $66.8 million in 2000 and $48.2 million in 1999. Research and development activities comprised 3% of total revenue in 2001, compared to 22% in 2000 and 28% in 1999.

Research and development revenue declined by 78% in 2001 compared to 2000, reflecting that after September 29, 2000 we did not earn any revenue from Intelligent Polymers. Research and development revenue increased by 39% in 2000 compared to 1999, reflecting expanded services rendered to Intelligent Polymers in 2000 as certain of the products under development advanced from the formulation development stage to scale-up, and into clinical trials. We earned revenue of $52.9 million from Intelligent Polymers for the period ended September 29, 2000 and $29.0 million in 1999.

In the ordinary course of business we enter into research and development arrangements with third parties whereby we provide contract research, formulation development and other services to those third parties. We are typically compensated on the basis of a fee for service, milestone payments, royalties from future sales of the product(s) or co-promotion revenue, or some combination of these.

In the years presented, the remaining research and development revenue was primarily generated from clinical research and laboratory testing services provided to external customers by our contract research operation. In addition, in 2001 we earned the final $2 million milestone payment from H. Lundbeck A/S for the development of a controlled-release formulation of the anti-depressant citalopram, and in 1999 we earned $4.8 million from Teva related to the development of certain generic controlled-release products.

Royalty and licensing activities generated revenue of $31.5 million, $17.3 million and $24.7 million, in 2001, 2000 and 1999, respectively. Royalty and licensing revenue comprised 5%, 6% and 14% of total revenue in 2001, 2000 and 1999, respectively.

Royalty and licensing revenue increased by 82% in 2001 compared to 2000, and declined by 30% in 2000 compared to 1999. The increase in royalty and licensing revenue in 2001 compared to 2000 reflected higher Tiazac® sales by our marketing partner Forest Laboratories Inc., and the inclusion of a royalty associated with sales of generic versions of Cardizem® by third parties. The decline in royalty and licensing revenue in 2000 compared to 1999 was due to reduced licensing activity as we began our strategy to direct market our branded products through our sales and marketing operations.

The following table displays, for each year indicated, the percentage of each expense item to total revenue, and the percentage change in the dollar amount of each item and the total as compared to the prior year. Prior to 2001, we included amortization expense as a component of cost of goods sold, research and development expenses and selling, general and administrative expenses. In 2001, amortization increased substantially due to recent additions to intangible assets and acquisitions of businesses, and consequently we decided to present amortization as an individual line item within operating expenses.

Cost of goods sold was $126.0 million in 2001, compared to $68.0 million in 2000 and $35.0 million in 1999, reflecting increases of 85% from 2000 to 2001, and 94% from 1999 to 2000. Cost of goods sold includes royalties on product sales payable to third party licensors that owned and/or developed the products. The year over year increases were the result of increased sales volumes from new product launches and product acquisitions, and higher sales levels of existing products.

Gross margins based on product sales in 2001, 2000 and 1999 were 77%, 70% and 65%, respectively. Our gross margins were impacted year to year by sales volumes, pricing, product mix, and manufacturing volumes. The increase in gross margin in 2001 compared to 2000 reflected the impact of the higher margin earned on Cardizem®, while the increase in gross margin in 2000 compared to 1999 reflected the significantly higher proportion of generic products relative to Tiazac® in the overall mix in 2000 compared to 1999, as generic products contributed higher margins than Tiazac®.

Research and development expenses were $51.0 million in 2001, compared to $51.7 million in 2000 and $33.0 million in 1999. As a percentage of total revenue, research and development costs declined to 9% in 2001 from 17% in 2000 and 19% in 1999. Research and development expenses reflect direct spending on the development of branded generic and generic products, and on rapid dissolve products utilizing our FlashDose® technology.

Although research and development expenses declined as a percentage of revenue in 2001, we are committed to continuing to devote the necessary resources towards our product pipeline. Our pipeline is progressing well as evidenced by our filing of three NDAs and three ANDAs for approval by the FDA, as well as a number of submissions to the TPD in Canada, since January 2001. In addition, Phase III clinical trials on once-daily branded generic versions of tramadol, indicated for the treatment of chronic pain, and buspirone, indicated for the treatment of generalized anxiety disorders, are ongoing. Research and development expenses in 2000 and 1999 included the costs associated with the development of branded generic products on behalf of Intelligent Polymers. The cost of providing those services to Intelligent Polymers was $35.2 million and $19.8 million in 2000 and 1999, respectively.

In the ordinary course of business, we enter into research and development arrangements with third parties to provide formulation and other services for our products under development. These third party developers are typically compensated on the basis of a fee for service, milestone payments, or royalty payments from the future sale of the products under development, or some combination of these.

During 2001, we entered into arrangements with unrelated third party formulating and product development companies. These arrangements target our therapeutic areas of focus (cardiovascular, pain management, central nervous system and niche opportunities) and typically include formulation and product development services being rendered by the developer in return for payments upon the attainment of predetermined milestones, and royalties on the net sales of the product(s) if and when commercialized. The developer may utilize its own technology and in other cases, we will supply access to our technology for the formulation and development of the product(s). In some cases, we have an ownership interest or an option to take an ownership position in the developer. In no case are we responsible for any of the developers' third party liabilities, nor have we guaranteed any debts, nor are we required under any circumstances to exercise any of our options.

Selling, general and administrative expenses were $110.1 million, $51.9 million and $36.2 million in 2001, 2000 and 1999, respectively. Selling, general and administrative expenses were 19% of total revenue in 2001, compared to 17% in 2000 and 21% in 1999. The 112% increase in selling, general and administrative expenses in 2001 compared to 2000 was mainly due to the inclusion of BPI's sales and marketing operation in our results for the full year. In addition, with the acquisition of Cardizem® the level of sales and marketing activity has increased at both BPI and BPC. In particular, BPI began preparing for an expansion of its sales force in the fourth quarter of 2001 in anticipation of the launch of Cardizem® XL in the second half of 2002. The 43% increase in selling, general and administrative expenses in 2000 compared to 1999 was mainly due to the acquisitions of DJ Pharma and Fuisz.

In December 2000, we entered into an agreement with Aventis to dismiss our lawsuit against them. Our lawsuit, which we initiated in 1998, alleged interference with our ability to market products that would compete with Cardizem® CD in the United States and Canada. Under the terms of the agreement, Aventis reimbursed us for expenses we incurred during 2000 in pursuing the litigation, and for other related expenses. A portion of these costs was included in selling, general and administrative expenses in the first three quarters of 2000. Accordingly, in the fourth quarter of 2000, we recorded the pertinent share of this reimbursement as a reduction to selling, general and administrative expenses. We did not record any amount in excess of the expenses we had directly incurred during 2000 related to this matter, nor did we receive any reimbursement for costs incurred during 1999.

Amortization expense was $44.5 million, $7.2 million and $2.8 million in 2001, 2000 and 1999, respectively. Amortization expense was 8% of total revenue in 2001 compared to 2% in 2000 and 1999.

The substantial increase in amortization expense between 2001 and 2000 reflected the amortization of product rights and goodwill associated with the acquisition of DJ Pharma, and the amortization of the Cardizem® brand name. In addition, amortization expense for 2001 includes the amortization of the exclusive marketing rights to Adalat acquired from Elan Corporation, plc ("Elan") in December 2000. In comparison, in the first nine months of 2000 we recorded revenue from Adalat product sales net of royalties paid to Elan. The increase in amortization expense between 2000 and 1999 reflected the amortization of the acquired technology and goodwill associated with the acquisition of Fuisz, and amortization associated with DJ Pharma from the date of acquisition.

In 2001, we recorded an $80.5 million non-cash charge primarily related to the write-down of the Keftab and Dura-Vent product rights associated with the acquisition of DJ Pharma.

At December 31, 2001, Eli Lilly had yet to resolve the manufacturing problems associated with Keftab. The supply interruption has resulted in a deterioration of customer awareness of the product, which would require substantial promotional efforts to restore when, and if, the product were to be re-launched. Due to these conditions that existed at December 31, 2001, we determined that the Keftab product right had been permanently impaired and should be written-down to its estimated recoverable value of $10 million. We recorded a related non-cash charge of $54.6 million.

We believe Eli Lilly is responsible for manufacturing and supplying acceptable products to us, as well as for the cost of the recall. In this regard, we have commenced a legal action against Eli Lilly in which we are seeking substantial damages as a result of Eli Lilly's voluntary recall of Keftab. We have not recorded any contingent amounts related to this action because we cannot ascertain what the outcome of this action will be.

In November 2000, the FDA requested a voluntary recall of products containing phenylpropanolamine ("PPA"). We immediately stopped shipments of our Dura-Vent products containing PPA and initiated a recall of these products from wholesalers and pharmacies. During 2001, we experienced supply interruptions resulting from manufacturing issues associated with our remaining Dura-Vent products that did not contain PPA. Dura-Vent is manufactured and supplied to us by a third party. These supply interruptions caused our revenues and gross margins for the remaining Dura-Vent products to significantly deteriorate. We evaluated the current and forecasted market share for the products and determined that the Dura-Vent product right had been permanently impaired and the remaining net book value should be written-off. We recorded a related non-cash charge of $19.0 million.

We recorded other write-downs of assets of $6.9 million primarily related to an intangible asset associated with the acquisition of Intelligent Polymers and our investment in Hemispherx Biopharma, Inc.

In 2000, we incurred a one-time charge for acquired research and development of $208.4 million as a result of our acquisition of Intelligent Polymers. In 1999, as a result of our acquisition of Fuisz, we incurred a one-time charge for acquired research and development of $137.5 million of which $56.8 million was included in the equity loss, and we expensed the $25 million paid to Intelligent Polymers for Procardia XL. Under GAAP, acquired research and development having no known alternative future use must be written-off at the time of acquisition.

Operating income was $171.2 million in 2001 compared to operating losses of $78.0 million and $40.2 million in 2000 and 1999, respectively. Operating income, excluding write-down of assets and acquired research and development, in 2001 was $251.6 million, an increase of $121.2 million or 93% from $130.4 million in 2000, which was $64.9 million or 99% higher than $65.5 million in 1999. As a percentage of total revenue, operating income, excluding write-down of assets and acquired research and development, increased to 43% in 2001 from 42% in 2000 and 38% in 1999. The increase was primarily due to a higher proportion of product sales, partially offset by incremental amortization related to those product sales.

Interest income of $2.7 million, $23.7 million and $5.4 million in 2001, 2000 and 1999, respectively, was earned on our investment portfolio, which is comprised primarily of high-grade government and corporate securities. Higher interest income in 2000 reflected a larger average investment portfolio following our concurrent offering of common shares and Debentures in March 2000, and prior to our acquisitions of Intelligent Polymers, Cardizem® and DJ Pharma.

Interest expense was $36.2 million, $20.7 million and $14.6 million in 2001, 2000 and 1999, respectively. Prior to March 2000, interest expense was primarily related to our Senior Notes. In March 2000, we redeemed our Senior Notes using the proceeds from our concurrent offering of common shares and Debentures and, accordingly, interest expense from this time related to the Debentures until their surrender and redemption

during the second half of 2001. In addition, interest expense in 2001 reflected interest on advances under our credit facility, and the amortization of the discounts on the Cardizem® and Adalat obligations. The non-cash amortization of these discounts amounted to $11.0 million.

In 2001, we recorded a debt conversion premium of $23.7 million, which represented the market value of the additional shares issued in excess of the number of shares that would have been issued under the terms of the conversion ratio provided for in the indenture governing the Debentures, upon the surrender of $173.8 million aggregate principal amount of our outstanding Debentures.

We recorded an additional debt conversion premium of $11.2 million, which represented the additional "make-whole" interest payment, on the remaining $126.1 million aggregate principal amount of our outstanding Debentures, which had been called for redemption.

In 1999, we disposed of certain long-term investments, which we had acquired in 1998, for a net gain of $1.9 million.

Our tax rate was affected by the relative profitability of our operations in various foreign tax jurisdictions. We recorded provisions for income taxes of $15.3 million, $9.4 million and $4.2 million in 2001, 2000 and 1999, respectively. The low effective tax rate was primarily due to most of our income being derived from foreign subsidiaries with lower statutory tax rates than those that apply in Canada. Following our acquisitions of DJ Pharma and Fuisz we have experienced some upward movement in our effective tax rate, as these operations predominately earn income in the United States.

In 2000, the total consideration paid to repurchase our Senior Notes was $141.0 million of which $16.0 million was an inducement premium to the holders. As a result of this transaction, we replaced our high yield debt with convertible debt at a significantly lower cost of borrowing. The extraordinary item reported in 2000 includes the premium paid, and $4.0 million of deferred financing costs associated with the Senior Notes that were written-off.

Effective January 1, 2000, we adopted SAB 101 and, accordingly, we changed our revenue recognition accounting policy for up-front research and development, product license and certain other fees. Historically, we had recognized these fees as revenue when all the conditions to payment had been met and there were no further performance contingencies or conditions to our receipt of payment. These fees were not creditable against future payments. At January 1, 2000, the cumulative effect of the change in accounting principle on prior years resulted in a charge of $43.5 million. The related deferred revenue recognized in 2001 and 2000 was $6.3 million and $9.3 million, respectively.

EBITDA, defined as earnings before interest, taxes, depreciation and amortization, is a non-GAAP measure that does not have a standardized meaning and, as such, may not be comparable to similarly titled measures presented by other companies. We utilize a measure of EBITDA that excludes write-down of assets, acquired research and development, debt conversion premiums, equity loss, net gains, extraordinary item and cumulative effect of change in accounting principle. The charges were excluded because they were considered to be of a non-operational nature in the applicable year. We disclose this measure of EBITDA to give investors an indication of our ability to meet debt service and capital expenditure requirements.

EBITDA, excluding certain charges, was $306.9 million, $151.4 million, and $73.7 million in 2001, 2000 and 1999, respectively. As a percentage of total revenue, EBITDA, excluding certain charges, increased to 53% in 2001 from 49% in 2000 and 43% in 1999.

We disclose the ratio of EBITDA, excluding certain charges, compared to interest expense because we believe it is a useful indication of our ability to meet debt service requirements. This ratio is not necessarily comparable to similarly titled measures presented by other companies. The ratio of EBITDA, excluding certain charges, to interest expense was 8.5 times, 7.3 times and 5.1 times for 2001, 2000 and 1999, respectively.

At December 31, 2001, we had cash and cash equivalents of $434.9 million compared to $125.1 million at December 31, 2000.

Cash provided by operating activities was $284.1 million in 2001 compared to $102.5 million and $52.0 million in 2000 and 1999, respectively. Net income, after adjustments for items not involving cash, was $262.8 million in 2001 compared to $149.7 million and $43.7 million in 2000 and 1999, respectively. Net changes in non-cash operating items provided cash of $21.3 million in 2001, mainly comprised of increases in accrued liabilities and income taxes payable offset by an increase in inventories, and $8.3 million in 1999, mainly comprised of increases in accounts payable and accrued liabilities offset by an increase in accounts receivable. Net changes in non-cash operating items used cash of $47.2 million in 2000, mainly comprised of an increase in accounts receivable and decreases in accounts payable and accrued liabilities.

Net cash used in investing activities was $57.7 million, $582.3 million and $107.5 million in 2001, 2000 and 1999, respectively. Additions to property, plant and equipment were $44.4 million, $15.8 million and $7.8 million in 2001, 2000 and 1999, respectively, and primarily related to the expansion of our manufacturing facilities. In 2001, we settled $4.0 million of acquisition costs related to Cardizem® and acquired other intangible assets for $23.4 million, offset by $15 million recovered as a reduction to the minimum license payments otherwise payable under the Adalat marketing rights agreement. In 2000, we acquired the remaining rights to the Dura-Vent, Keftab and Rondec products, and other product rights for $27.8 million, and we acquired product rights for $13.3 million in 1999. Cash expended on long-term investments was $0.9 million and $2.5 million in 2001 and 2000, respectively, and cash received on the disposal of long-term investments was $12.0 million in 1999. Business acquisitions, net of cash acquired, totaled $622.1 million in 2000 consisting of $239.7 million for Cardizem®, $202.4 million for Intelligent Polymers, $162.8 million for DJ Pharma, and $17.2 million of additional consideration paid for Fuisz, compared to $43.7 million in 1999 which was entirely related to Fuisz. The net activity in short-term investments provided cash of $65.9 million in 2000, and used cash of $54.7 million in 1999. In 2000, as our short-term investments matured we converted them into cash equivalents with original maturities of 90 days or less. In 2000, we received proceeds of $20 million on the disposal of Clonmel Healthcare Limited, a subsidiary of Fuisz.

Net cash provided by financing activities was $83.6 million, $427.1 million and $155.0 million in 2001, 2000 and 1999, respectively. Net proceeds from our equity offerings in November 2001, March 2000 and October 1999 were $560.0 million, $95.3 million and $246.1 million, respectively. Proceeds from the issue of common shares on the exercise of stock options and through our Employee Stock Purchase Plan were $29.2 million, $14.3 million and $7.6 million in 2001, 2000 and 1999, respectively. We repurchased common shares on the open market, under our share repurchase programs, for $120.0 million and $30.6 million in 2001 and 1999, respectively. In 2001, we made loans in an aggregate amount of $10.0 million to certain executive officers under our Executive Stock Purchase Plan ("ESPP") and received repayments of ESPP loans of $3.1 million in 1999. We received proceeds of $29.1 million and $6.0 million on the exercise of warrants in 2001 and 2000, respectively. We collected $2.3 million and $4.0 million of the warrant subscription receivable in 2000 and 1999, respectively. We made net repayments of $210 million under our credit facility in 2001, and paid additional financing costs of $1.3 million related to the increase in the credit facility from $300 million to $400 million. In 2000, we borrowed $210 million from our credit facility, and paid $3 million in arrangement fees. In 2001, we repaid $193.4 million of other long-term obligations, including the four quarterly Cardizem® obligation installments of $42.5 million each, and $22.9 of the Adalat obligation. In 2000, we repaid the debt assumed on the acquisition of DJ Pharma and other long-term obligations of $45.6 million. In 1999, we repaid the debt assumed on the acquisition of Fuisz

and other long-term obligations of $75.2 million. In 2000, we received net proceeds of $288.8 million from the issue of Debentures, and repurchased our Senior Notes for $141.0 million.

Overall, our cash and cash equivalents increased by $309.7 million and $99.8 million in 2001 and 1999, respectively, and decreased by $52.9 million in 2000.

In 2001, non-cash investing and financing activities included the issuance of common shares valued at $314.3 million on the surrender and redemption of Debentures. In 2000, non-cash investing and financing activities included the $161.8 million discounted obligation assumed on the acquisition of Cardizem®, $4.0 million of accrued Cardizem® acquisition costs, and the $58.1 million discounted obligation in connection with the acquisition of the Adalat marketing rights. In 1999, non-cash investing and financing activities consisted of the issuance of common shares valued at $88.2 million on the acquisition of Fuisz.

In June 2001, our revolving term credit facility was successfully syndicated and was increased from $300 million to $400 million. In November 2001 we negotiated an extension of the credit facility and an improvement in the terms related to certain covenants. At December 31, 2001, we were in compliance with all financial and non-financial covenants associated with the credit facility.

In November 2001, Standard & Poor's Rating Services, a division of The McGraw-Hill Companies, Inc., ("S&P") raised our corporate credit rating to BB from BB-. On March 25, 2002, S&P raised our corporate credit rating to BB+ from BB.

At December 31, 2001, we had total long-term obligations of $46.2 million, including the current portion thereof, which consisted of the remaining $38.6 million Adalat obligation and $7.5 million of deferred compensation.

During 2001, we entered into privately negotiated agreements with certain holders of our outstanding Debentures. These agreements provided for the issuance of 6,278,663 common shares to those certain Debenture holders upon their surrender of $173.8 million aggregate principal amount of outstanding Debentures. Following the surrender of Debentures, $126.1 million aggregate principal amount of Debentures remained outstanding. In October 2001, we announced our intention to exercise our option to redeem the remaining Debentures under the terms of the special redemption provisions of the indenture governing the Debentures. Substantially all of the remaining Debentures were converted into 4,154,564 of our common shares prior to the redemption date.

During 2001, we entered into privately negotiated agreements with certain holders of our outstanding warrants. Those agreements provided for the exercise of 758,300 warrants to purchase 3,033,200 common shares. As an inducement to those certain warrant holders to exercise, we paid such warrant holders less than a 5% inducement, approximately equal to our cost of borrowing, per warrant exercised. In aggregate, we received proceeds of $28.8 million net of the inducement cost of $1.5 million.

In September 2001, we implemented a common share repurchase program pursuant to which we were able to repurchase up to $120 million of our issued and outstanding common shares. In aggregate, 2,871,200 common shares were repurchased under this program, through open market transactions on the New York Stock Exchange ("NYSE"), at an average purchase price of $41.79 for total consideration of $120.0 million. The excess of the cost of the common shares acquired over the stated capital thereof, totaling $105.6 million was charged to the deficit.

On November 5, 2001, we filed a $1.5 billion base shelf prospectus with the Canadian provincial securities commissions covering the potential sale of any combination of common shares, debt securities or warrants. On the same date, we filed a registration statement on Form F-10 covering those securities with the SEC under the multijurisdictional disclosure system. We may offer one or more of these types of securities in one or more offerings during the succeeding 25 months. One or more shareholders may also sell common shares pursuant to the base shelf prospectus. We will not receive any of the proceeds from any sale of common shares by the selling shareholders.

In November 2001, we issued 12,500,000 common shares for gross proceeds of $587.5 million under our base shelf prospectus.

In February 2002, by resolution of the Board of Directors we implemented a common share repurchase program pursuant to which we are able to repurchase up to 5% or approximately 7,850,000 of our issued and outstanding common shares. To April 17, 2002, an aggregate 5,657,100 common shares had been repurchased under this program, through open market transactions on the NYSE, at an average purchase price of $46.01 for total consideration of $260.3 million. The excess of the cost of the common shares acquired over the stated capital thereof, totaling $209.7 million was charged to the deficit.

In March 2002, we issued $400 million aggregate principal amount of unsecured Notes under our base shelf prospectus. Interest on the Notes is payable semi-annually in arrears on April 1 and October 1 of each year, beginning October 1, 2002. The Notes were issued at a price of 99.27% of their aggregate principal amount for an effective yield, if held to maturity, of 8%.

At any time on or after April 1, 2006, we may redeem all or any of the Notes at prescribed prices, plus accrued and unpaid interest to the date of redemption. Before April 1, 2005, we may redeem up to 35% of the original principal amount of the Notes, with the net cash proceeds of certain sales of our common shares, at 107.875% of the principal amount plus accrued and unpaid interest to the date of redemption.

We have a balance of $512.5 million available under our base shelf prospectus to offer at our discretion.

We believe we have adequate capital resources and sources of financing to support our ongoing operational and interest requirements, investment objectives and to meet our obligations as they become due. We believe we will be able to raise additional capital, if necessary, to support our objectives.

We are exposed to financial market risks, including changes in foreign currency exchange rates, interest rates on investments and debt obligations and equity market prices on long-term investments. We do not use derivative financial instruments for speculative or trading purposes.

We operate internationally, however a substantial portion of our revenue and expense activities and capital expenditures are transacted in U.S. dollars. Our only other significant transactions are in Canadian dollars, and we do not believe we have a material exposure to foreign currency risk because of the relative stability of the Canadian dollar in relation to the U.S. dollar. A 10% adverse change in foreign currency exchange rates would not have a material effect on our consolidated results of operations, financial position, or cash flows.

The primary objective of our investment policy is the protection of principal, and accordingly we invest in high-grade government and corporate securities with varying maturities, but typically less than 90 days. External independent fund administrators manage our investments. As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate risk. Therefore, a 100 basis-point adverse change in interest rates would not have a material effect on our consolidated results of operations, financial position, or cash flows.

We are exposed to interest rate risk on borrowings from our credit facility. The credit facility bears interest based on LIBOR, U.S. dollar base rate, Canadian dollar prime rate, or Canadian dollar Bankers' Acceptances. Based on projected advances under the credit facility, a 100 basis-point adverse change in interest rates would not have a material effect on our consolidated results of operations, financial position, or cash flows. This risk is mitigated by our ability, at our option, to lock in a rate of interest for a period of up to one year.

The interest rate on our Notes is fixed and therefore not subject to interest rate risk. Likewise, the imputed rate of interest used to discount our Adalat long-term obligation is fixed and therefore not subject to interest rate risk.

We are exposed to equity market price risks on our long-term, available-for-sale investments in traded companies. We do not hold significant investments in these types of securities, and therefore our equity market price risk is not material. Therefore, a 10% adverse change in equity market prices would not have a material effect on our consolidated results of operations, financial position, or cash flows.

In June 2001, the FASB issued SFAS No. 141, "Business Combinations", and SFAS No. 142, "Goodwill and Other Intangible Assets", effective for fiscal years beginning after December 15, 2001. Under SFAS No. 141, all business combinations occurring after June 30, 2001 are to be accounted for under the purchase method of accounting. Under SFAS No. 142, goodwill and other intangible assets deemed to have indefinite lives will no longer be amortized, but will be subject to annual impairment tests. Other intangible assets will continue to be amortized over their estimated useful lives.

We will adopt SFAS No. 142 as of January 1, 2002 as required. We will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of January 1, 2002. Any impairment loss for goodwill and indefinite lived intangible assets arising from the initial application of SFAS No. 142 is to be reported as resulting from a change in accounting principle.

In accordance with SFAS No. 142, we are in the process of: (a) assessing the useful lives of our intangible assets, including identifying any intangible assets with indefinite lives; (b) identifying intangible assets that do not meet the criteria for recognition apart from goodwill that will be reclassified to goodwill, and intangible assets that meet the criteria for recognition apart from goodwill but have been aggregated with goodwill that will be reclassified and reported separately from goodwill; and (c) determining the cumulative effect of the change in accounting principle as of January 1, 2002.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", effective for fiscal years beginning after December 15, 2001. SFAS No. 144 addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of", and the accounting and reporting provisions of Accounting Principles Board Opinion No. 30, "Reporting the Results of Operations for a disposal of a segment of a business". We expect to adopt SFAS No. 144 as of January 1, 2002 and have not determined the effect, if any, the adoption of SFAS No. 144 will have on our financial position and results of operations.

To the extent any statements made in this document contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks. Many risks and uncertainties are inherent in the pharmaceutical industry; others are more specific to our business. Many of the significant risks related to our business are described in Item 3 of our Form 20-F filing with the SEC.

The Company's management is responsible for preparing the accompanying consolidated financial statements in conformity with United States generally accepted accounting principles ("GAAP"). In preparing these consolidated financial statements, management selects appropriate accounting policies and uses its judgement and best estimates to report events and transactions as they occur. Management has determined such amounts on a reasonable basis in order to ensure that the consolidated financial statements are presented fairly, in all material respects. Financial data included throughout this Annual Report is prepared on a basis consistent with that of the consolidated financial statements.

The Company maintains a system of internal accounting controls designed to provide reasonable assurance, at a reasonable cost, that assets are safeguarded and that transactions are executed and recorded in accordance with the Company's policies for doing business. This system is supported by written policies and procedures for key business activities; the hiring of qualified, competent staff; and by a continuous planning and monitoring program.

Ernst & Young LLP has been engaged by the Company's shareholders to audit the consolidated financial statements. During the course of their audit, Ernst & Young LLP reviewed the Company's system of internal controls to the extent necessary to render their opinion on the consolidated financial statements.

The Board of Directors is responsible for ensuring that management fulfills its responsibility for financial reporting and is ultimately responsible for reviewing and approving the financial statements. The Board carries out the responsibility principally through its Audit Committee. The members of the Audit Committee are outside Directors. The Committee considers, for review by the Board of Directors and approval by the shareholders, the engagement or reappointment of the external auditors. Ernst & Young LLP has full and free access to the Audit Committee.

Management acknowledges its responsibility to provide financial information that is representative of the Company's operations, is consistent and reliable, and is relevant for the informed evaluation of the Company's activities.

We have audited the consolidated balance sheets of Biovail Corporation as at December 31, 2001 and 2000 and the consolidated statements of income (loss), shareholders' equity and cash flows for each of the years in the three-year period ended December 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian and United States generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2001 and 2000 and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2001 in accordance with United States generally accepted accounting principles.

On April 17, 2002, we reported separately to the shareholders of Biovail Corporation on the consolidated financial statements for the same periods, prepared in accordance with Canadian generally accepted accounting principles.

TABLE 5-01 Consolidated Balance Sheets
In accordance with U.S. generally accepted accounting principles
As at December 31
(All dollar amounts expressed in thousands of U.S. dollars)

The accompanying notes are an integral part of the consolidated financial statements.

TABLE 5-02 Consolidated Statements of Income (Loss)
In accordance with U.S. generally accepted accounting principles
Years ended December 31
(All dollar amounts expressed in thousands of U.S. dollars, except per share data)

The accompanying notes are an integral part of the consolidated financial statements.

TABLE 5-03 Consolidated Statements of Shareholders' Equity
In accordance with U.S. generally accepted accounting principles
(All dollar amounts expressed in thousands of U.S. dollars)

TABLE 5-03 Consolidated Statements of Shareholders' Equity (Continued)
In accordance with U.S. generally accepted accounting principles
(All dollar amounts expressed in thousands of U.S. dollars)

The accompanying notes are an integral part of the consolidated financial statements.

TABLE 5-04 Consolidated Statements of Cash Flows
In accordance with U.S. generally accepted accounting principles
Years ended December 31
(All dollar amounts expressed in thousands of U.S. dollars)

The accompanying notes are an integral part of the consolidated financial statements.

IN ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES
(Tabular amounts in thousands of U.S. dollars, except for number of shares and per share data)

Biovail Corporation ("Biovail" or the "Company") is incorporated under the laws of the Province of Ontario, Canada. The Company is a fully integrated pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of medications utilizing advanced drug delivery technologies for the treatment of chronic medical conditions. The Company's common shares trade on the New York Stock Exchange ("NYSE") and the Toronto Stock Exchange.

The consolidated financial statements have been prepared by the Company in U.S. dollars and in accordance with U.S. generally accepted accounting principles ("GAAP"), applied on a consistent basis. Consolidated financial statements prepared in U.S. dollars and in accordance with Canadian GAAP are made available to all shareholders and filed with various regulatory authorities.

The consolidated financial statements include the accounts of the Company and those of all its subsidiaries. All significant intercompany transactions and balances have been eliminated.

In preparing the Company's consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated finan-cial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates made by management include the calculation of reserves for uncollectible accounts, product recalls, returns, rebates and allowances, useful lives of long-lived assets, including intangibles, and the realizability of deferred tax assets.

The estimated fair value of all financial assets and liabilities, other than the Convertible Subordinated Preferred Equivalent

Debentures, approximates their carrying values at December 31, 2001 and 2000. Fair value of a financial instrument is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties.

Cash and cash equivalents include highly liquid investments with original maturities of 90 days or less when purchased. Cash equivalents are carried at cost, which approximates fair value.

Inventories are comprised of raw materials, work in process and finished goods, which are valued at the lower of cost and replacement cost, on a first-in, first-out basis. The costs of raw materials and acquired finished goods inventories are the purchase price of the product and attributable direct costs, less trade discounts. The cost of manufactured inventory includes the purchase price of raw materials, direct labor, and the application of attributable overheads.

Long-term investments are generally classified as available-for-sale in accordance with the Financial Accounting Standards Board ("FASB") Statement of Financial Accounting Standards ("SFAS") No. 115, "Accounting for Certain Investments in Debt and Equity Securities". Long-term investments are reported at fair value with temporary unrealized gains and losses on these investments included in accumulated other comprehensive loss in shareholders' equity. Unrealized losses on these investments that are considered to be other than temporary are recognized in net income (loss).

Property, plant and equipment are reported at cost, less accumulated depreciation. Cost includes interest costs attributable to major capital projects prior to the projects becoming available for productive use. Depreciation is computed using the straight-line method based on the following estimated useful lives:


Buildings		25 years
Machinery and equipment		5-10 years
Other equipment		3-5 years
Leasehold improvements		term of lease

Goodwill represents the excess of the purchase price of acquired businesses over the fair value of the identifiable net assets acquired. Intangible assets acquired through business combinations are initially

recognized at fair value based upon an allocation of the purchase price. Intangible assets acquired other than through business combinations are initially recognized at fair value based upon the consideration paid.

Goodwill and intangible assets are reported at cost, less accumulated amortization. Amortization is computed using the straight-line method based on the following estimated useful lives:


Goodwill		20 years
Workforce		6-10 years
Core technology		15 years
Brand names		20 years
Product rights and royalty interests		10-20 years

In accordance with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of", the Company reviews long-lived identifiable assets and related goodwill for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable by comparing the carrying amounts to the related estimated undiscounted future net cash flows. If the undiscounted future net cash flows are less than the carrying amount of a long-lived asset, the carrying amount of the long-lived asset is written-down to fair value.

Effective with the adoption of SFAS No. 142, "Goodwill and Other Intangible Assets", on January 1, 2002, goodwill and certain other intangible assets will no longer be amortized but will be subject to annual impairment tests (as described in this note under recent accounting pronouncements).

Other assets include deferred financing costs, which are reported at cost, less accumulated amortization. Deferred financing costs are amortized over the term of the following related debt:


Revolving term credit facility		3 years
Convertible Subordinated Preferred Equivalent Debentures		25 years

Amortization expense related to deferred financing costs is included as a component of interest expense.

During 2001, in connection with the surrender and redemption of the Convertible Subordinated Preferred Equivalent Debentures, the related unamortized deferred financing costs were included in the valuation of the common shares issued.

The liability method of accounting for income taxes is used in accordance with SFAS No. 109, "Accounting for Income Taxes". Under this method, deferred tax assets and liabilities are recognized for the differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets which are "more-likely-than-not" to be unrealized. Deferred tax assets and liabilities are measured using the enacted tax rates and laws.

Product sales — Product sales revenue is recognized when the product is shipped to the customer, provided the Company has not retained any significant risks of ownership or future obligations with respect to the product shipped. Revenue from product sales is recognized net of sales discounts and allowances. In certain circumstances the Company allows customers to return or exchange products. In accordance with SFAS No. 48, "Revenue Recognition When Right of Return Exists", the Company maintains provisions for estimated product returns or exchanges. Amounts received from customers as prepayments for products to be shipped in the future are reported as deferred revenue.

Research and development — Research and development revenue attributable to the performance of contract services is recognized as the services are performed, in accordance with the terms of the specific development contract. On long-term research and development arrangements, revenue is recognized relative to the total level of effort necessary to meet all regulatory and developmental requirements. Costs and related profit margin in excess of amounts billed are included in accounts receivable. Amounts billed in excess of costs and related profit margin are included in deferred revenue. Non-refundable, up-front fees for access to the Company's proprietary technology in connection with certain research and development arrangements are deferred and recognized as revenue on a straight-line basis over the term of the related arrangement.

Royalty and licensing — Royalty revenue is recognized on an accrual basis in accordance with the contractual agreements and when the Company has no future obligations pursuant to the royalty fee. Royalty revenue is net of amounts payable to sublicensees where the Company is simply acting as an agent for the sublicensee. License revenue is deferred and recognized on a straight-line basis over the license period. If there are future performance obligations of the Company, or contingent future events relating to the amounts received or receivable under the license agreements, revenue attributable to these obligations or future events is deferred and recognized upon the completion of the specific event.

In accordance with SFAS No. 2, "Accounting for Research and Development Costs", research and development costs are expensed in the period in which they are incurred. Acquired research and development having no alternative future use is written-off at the time of acquisition. The cost of intangible assets that are purchased from others for a particular research and development project that have no alternative future use is written-off at the time of acquisition.

Advertising and promotion costs related to new product launches are expensed upon the first showing of the product. Advertising expense for 2001, 2000 and 1999 was $3,957,000, $3,434,000 and $4,955,000, respectively. At December 31, 2001 and 2000, deferred advertising costs reported in assets were nil.

The Company presents its consolidated financial statements in U.S. dollars. The financial statements of the parent company and its non-U.S. subsidiaries are translated into U.S. dollars in accordance with SFAS No. 52, "Foreign Currency Translation". Asset and liability accounts are translated at the rate of exchange prevailing at the balance sheet date. Shareholders' equity accounts are translated at the applicable historical rate. Revenue and expense accounts are translated at the average rate of exchange for the year. The cumulative foreign currency translation adjustment is reported as a component of accumulated other comprehensive loss in shareholders' equity. The net change in the cumulative foreign currency translation adjustment in the periods presented is primarily due to fluctuations in the exchange rates between the Company's reporting currency and the Canadian dollar, Irish pound and Swiss franc.

Foreign currency transaction gains and losses are included in net income (loss) and are immaterial for all periods presented.

Under the provisions of SFAS No. 123, "Accounting for Stock Compensation", companies can either measure the compensation cost of equity instruments issued under employee compensation plans using a fair value based method or can continue to recognize compensation cost using the intrinsic value method under the provisions of Accounting Principles Board Opinion ("APB") No. 25, "Accounting for Stock Issued to Employees". However, if the provisions of APB No. 25 are applied, pro forma disclosure of net income (loss) and earnings (loss) per share must be presented in the financial statements as if the fair value method had been applied. For all periods presented, the Company recognized compensation costs under the provisions of APB No. 25 and has provided the expanded disclosure required by SFAS No. 123.

In June 2001, the FASB issued SFAS No. 141, "Business Combinations", and SFAS No. 142, effective for fiscal years beginning after December 15, 2001. Under SFAS No. 141, all business combinations occurring after June 30, 2001 are to be accounted for under the purchase method of accounting. Under SFAS No. 142, goodwill and other intangible assets deemed to have indefinite lives will no longer be amortized, but will be subject to annual impairment tests. Other intangible assets will continue to be amortized over their estimated useful lives.

The Company will adopt SFAS No. 142 as of January 1, 2002 as required. The Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of January 1, 2002. Any impairment loss for goodwill and indefinite lived intangible assets arising from the initial application of SFAS No. 142 is to be reported as the cumulative effect of a change in accounting principle.

In accordance with SFAS No. 142, the Company is in the process of: (a) assessing the useful lives of its intangible assets, including identifying any intangible assets with indefinite lives; (b) identifying intangible assets that do not meet the criteria for recognition apart from goodwill that will be reclassified to goodwill, and intangible assets that meet the criteria for recognition apart from goodwill but have been aggregated with goodwill that will be reclassified and reported separately from goodwill; and (c) determining the cumulative effect of the change in accounting principle as of January 1, 2002.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", effective for fiscal years beginning after December 15, 2001. SFAS No. 144 addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS No. 121 and the accounting and reporting provisions of APB No. 30, "Reporting the Results of Operations for a disposal of a segment of a business". The Company expects to adopt SFAS No. 144 as of January 1, 2002 and has not determined the effect, if any, the adoption of SFAS No. 144 will have on the Company's financial position and results of operations.

Effective January 1, 2000, the Company implemented the provisions of the U.S. Securities and Exchange Commission's Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements". Accordingly, the Company changed its method of accounting to that described in the revenue recognition accounting policy for up-front research and development, product license and certain other fees. The Company historically recognized these fees as revenue when all the conditions to payment had been met, and there were no further performance contingencies or conditions to the Company's receipt of payment. These fees were not creditable against future payments. At January 1, 2000, the cumulative effect of the change in accounting principle on prior years resulted in a charge of $43,500,000, which is included in the net loss for 2000. Of this amount, $6,300,000 and $9,300,000 are included in revenue for 2001 and 2000, respectively. The remaining cumulative effect adjustment has been recorded as deferred revenue.

Actual and pro forma amounts assuming change in accounting principle was applied retroactively with restatement are as follows:

		Actual		Pro forma
Net loss		$	(109,978	)	$	(121,378	)
Basic and diluted loss per share			(1.07	)		(1.18	)

Effective January 1, 2001, the Company implemented SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities". SFAS No. 133 requires a company to recognize all derivative instruments as assets or liabilities in its balance sheet and to measure them at fair value. The adoption of SFAS No. 133 did not result in any cumulative effect adjustment in the consolidated statements of income (loss), and did not have a material impact on the Company's financial position or results of operations as the Company does not use derivative financial instruments or engage in hedging activities.

During 2000, the Company completed the acquisitions of Intelligent Polymers Limited ("Intelligent Polymers"), the Cardizem® product line ("Cardizem®") and DJ Pharma, Inc. ("DJ Pharma"). These

acquisitions were accounted for under the purchase method of accounting. Total consideration, including acquisition costs, was allocated based on estimated fair values on the respective dates of acquisition, as follows:

In July 1997, Intelligent Polymers, a Bermuda corporation was formed primarily to develop once-daily, controlled-release branded versions of selected drugs whose chemical patents and/or exclusivity periods had or were about to expire and which were marketed only in immediate-release form or in controlled-release form requiring multiple daily dosing.

In September 1997, the Company concluded a development and license agreement (the "Development Contract") and a services agreement with Intelligent Polymers, whereby the Company would develop the designated products on Intelligent Polymers' behalf.

In an initial public offering in October 1997, 3,737,500 units of Intelligent Polymers were sold to the public, resulting in net proceeds to Intelligent Polymers, after offering costs, of approximately $69,500,000. The

proceeds of the offering were used by Intelligent Polymers to make payments to the Company under the Development Contract.

Payments received by the Company from Intelligent Polymers pursuant to the Development Contract were $55,200,000 for the period ended September 29, 2000, and $33,000,000 for the year ended December 31, 1999. The cost of providing those services to Intelligent Polymers was $35,200,000 for the period ended September 29, 2000, and $19,800,000 for the year ended December 31, 1999.

In December 1999, the Company exercised its option to acquire the rights to the generic version of Procardia XL, developed on behalf of Intelligent Polymers, for $25,000,000. The right to Procardia XL was written-off as acquired research and development in 1999 since at the time of the acquisition the product had not received regulatory approval from the U.S. Food and Drug Administration ("FDA"), and had no alternative future use.

The Company, as the holder of all of the issued and outstanding special shares of Intelligent Polymers, was entitled, at its sole discretion, to purchase all, but not less than all, of the outstanding common shares of Intelligent Polymers commencing on the closing date of the offering and ending on the earlier of September 30, 2002, or the 90th day after the date Intelligent Polymers provided the Company with quarterly financial statements showing cash or cash equivalents of less than $3,000,000. The purchase price calculated on a per share basis would have been as follows:

	Purchase price
Before October 1, 2000	$	39.06
On or after October 1, 2000 and on or before September 30, 2001		48.83
On or after October 1, 2001 and on or before September 30, 2002		61.04

On September 29, 2000, the Company sold all of its interest in and to the special shares of Intelligent Polymers to IPL Acquireco 2000 Ltd., a British Virgin Islands company ("IPL Acquireco"), in exchange for 12,000 non-voting common shares of IPL Acquireco, valued at $12,000. In addition, the Company invested $141,500,000 in non-voting Class A shares of IPL Acquireco. On the same date, IPL Acquireco, as holder of the special shares of Intelligent Polymers, consummated the purchase of all the issued and outstanding common shares of Intelligent Polymers and thereby Intelligent Polymers became a wholly-owned subsidiary of IPL Acquireco. As a result of IPL Acquireco's acquisition of Intelligent Polymers, certain provisions of the Development Contract were amended such that Intelligent Polymers took over the development of the designated products, including directly contracting with, and making payments to, third parties.

The Company, as holder of all of the non-voting common shares of IPL Acquireco, was entitled, at its sole discretion, to purchase all of the voting common shares of IPL Acquireco at any time prior to October 1, 2002. IPL Acquireco had 6,500,000 voting common shares issued and outstanding.

On December 29, 2000, the Company purchased all the voting common shares of IPL Acquireco for total consideration of $6,750,000. Contemporaneously with the acquisition of IPL Acquireco, the Company repaid the bank credit facility of Intelligent Polymers, which amounted to $56,616,000. Accordingly, the total consideration for the acquisition of IPL Acquireco, including the value of the Class A and special shares, was $204,878,000. The assets, liabilities and expenses of IPL Acquireco and Intelligent Polymers have been included in these consolidated financial statements from December 29, 2000.

At the date of acquisition, the products under development were in various stages of completion, had not reached technological feasibility and had no known alternative uses, and were considered to be in-process research and development. The efforts required to develop the acquired research and development into commercially viable products include the completion of the development stages of the products, clinical-trial testing, FDA approval, and commercialization. The principal risks relating to the products in development are the outcomes of the formulation development, clinical studies and regulatory filings. At the date of acquisition, none of the products had been submitted for approval with the FDA. Since pharmaceutical products cannot be marketed without regulatory approvals, the Company will not receive any benefits unless regulatory approval is obtained.

Biovail is continuing the development programs for the various products previously being developed for Intelligent Polymers. Two of these developmental programs are now in Phase III clinical trials (tramadol and buspirone), and another (bupropion) has been licensed to GlaxoSmithKline plc ("GSK") as described in note 25 — Research and Development Arrangements.

Intelligent Polymers had acquired as part of its development activities the rights to a cardiovascular product. This product right was included in the value of the net liabilities assumed of Intelligent Polymers.

The following unaudited pro forma information presents a summary of the consolidated results of operations of the Company, IPL Acquireco and Intelligent Polymers as if the acquisition had occurred on

January 1, 1999. Included in the consolidated results for 1999 is the write-off of acquired research and development. All transactions between the Company and Intelligent Polymers have been eliminated.

	2000		1999
Total revenue	$	255,946		$	143,492
Net loss		(13,171	)		(345,391	)
Basic and diluted loss per share		(0.10	)		(3.37	)

These unaudited pro forma consolidated results have been prepared for comparative purposes only. They do not purport to be indicative of the results of operations which actually would have resulted had IPL Acquireco and Intelligent Polymers been included in the Company's consolidated financial statements from January 1, 1999. In addition, they do not purport to be indicative of future consolidated results of operations of the Company.

On December 28, 2000, the Company acquired the North American rights to Cardizem® from Aventis Pharmaceuticals, Inc. and its affiliates ("Aventis"). Cardizem® is a leading calcium channel blocker prescribed for the treatment of hypertension and angina. The Company acquired all of the intangible assets associated with the products including the patents, regulatory files, trademarks, manufacturing know-how, copyrights and other intellectual property. The Company obtained the beneficial rights to and the interest in Cardizem® effective December 31, 2000, and obtained full legal rights and title on December 31, 2001, following the completion of the payments described below.

The purchase price for Cardizem® was $409,500,000 in cash comprised of an initial payment of $239,500,000, and the balance of $170,000,000 payable equally over the four quarters of 2001. In accordance with APB No. 21, "Interest on Receivables and Payables", the remaining payments were present valued based on an imputed interest rate of approximately 8%, which was comparable to the Company's available borrowing rate as at the date of the transaction. Accordingly, the present value of the remaining payments was determined to be $161,828,000, resulting in a discount of $8,172,000. The total discounted purchase price was $406,070,000, including costs of acquisition of $4,742,000, and was allocated entirely to intangible assets. The intangible assets will be amortized over their estimated useful lives of twenty years.

In connection with the acquisition, the Company entered into manufacturing and transitional services agreements with Aventis. The terms of these agreements are summarized as follows:

Aventis will manufacture and package, or cause another party to manufacture and package, Cardizem® for sale by the Company. The term of the agreement is from January 1, 2001 to December 31, 2003, with a right to extend the term at the Company's option, subject to certain conditions, if by the end of the term the Company is unable to successfully manufacture Cardizem® on its own behalf, or is unable to reach an agreement with a second source supplier. In addition to the manufacturing supply price, the Company agreed to pay additional amounts under the manufacturing agreement of $5,000,000, $3,000,000 and $2,000,000 on January 2, 2001, 2002 and 2003, respectively, which are not directly attributable to any specified manufacturing volume and are incremental to the existing fair value supply price per unit.

Aventis agreed to reimburse the Company the sum of $21,000,000 for transitional expenses incurred by the Company. During 2001, the Company applied $11,275,000 of the sum to recompense the $5,000,000 paid under the manufacturing agreement, as described above, and the balance as a reimbursement of other incremental transitional costs incurred. The remaining $9,725,000 has been recorded in accrued liabilities and has been specifically allocated to the future payments under the manufacturing agreement and for other unconditional obligations assumed from Aventis at the time of the acquisition.

The following unaudited pro forma information presents a summary of the consolidated results of operations of the Company including the contribution from Cardizem® as if the acquisition had occurred on January 1, 1999. The contribution includes only direct expenses related to Cardizem® and, as such, does not include any allocation of indirect selling, general and administrative expenses. A full year of amortization, and interest expense on advances under the revolving term credit facility, is included in the consolidated results of both periods presented. Included in the consolidated results of 1999 is the amortization of the imputed interest on the Cardizem® obligation.

	2000
Total revenue	$	567,325	$	819,964
Net income		2,254		306,266
Basic earnings per share		0.02		2.99
Diluted earnings per share		0.02		2.83

contribution from Cardizem® been included in the Company's consolidated financial statements from January 1, 1999. In addition, they do not purport to be indicative of future consolidated results of operations of the Company.

On October 6, 2000, the Company acquired DJ Pharma for $165,127,000, including costs of acquisition of $868,000 and the fair value of unvested DJ Pharma employee stock options. In accordance with FASB Interpretation ("FIN") No. 44, "Accounting for Certain Transactions Involving Stock Compensation," the total fair value of the unvested options granted to employees of DJ Pharma was determined to be $7,480,000, of which $1,759,000 was allocated to the purchase price, and $5,721,000 was allocated to deferred compensation, based on the ratios of the past and future service periods divided by the total service period, respectively. The assets, liabilities, revenue and expenses of DJ Pharma have been included in the consolidated financial statements of the Company from October 6, 2000.

DJ Pharma was organized to market and sell patented and branded generic prescription pharmaceutical products for the treatment of respiratory and allergy conditions, and for skin and soft tissue infections. DJ Pharma obtained the rights to certain products from Dura Pharmaceuticals, Inc. and one of its subsidiaries ("Dura"). The products obtained from Dura included a patented broad-spectrum antibiotic ("Keftab") used primarily for the treatment of respiratory and skin infections developed by Eli Lilly & Company ("Eli Lilly"); a line of prescription cough, cold and allergy branded generic products ("Dura-Vent") developed by Dura; and a line of prescription cough, cold and allergy branded generic products ("Rondec") developed by Abbot Laboratories. DJ Pharma also had the exclusive rights to sell and market Schering Corporation's ("Schering") antibiotic Cedax in the United States. Cedax is an antibiotic indicated for the treatment of chronic bronchitis, middle ear infection and tonsillitis.

DJ Pharma had an assembled workforce mainly involved in the sales and marketing of its products.

At the acquisition date, the Company obtained the services of approximately 300 DJ Pharma employees, consisting primarily of sales account managers and representatives. The assembled workforce was fair valued using a cost approach, and is estimated to have a useful life of six years.

At the acquisition date, DJ Pharma had various purchase, licensing and supply agreements covering branded products and product families such as Keftab, Dura-Vent, Rondec and Cedax. These contracts provided the Company with a stream of identifiable benefits resulting from the sale of these products. Under the

agreement with Dura, DJ Pharma obtained exclusive rights to Keftab, Dura-Vent and Rondec through to December 31, 2002, in return for payment of certain license fees based on a percentage of net sales, subject to annual minimums and maximums (the "Dura Agreement"). At the expiration of the Dura Agreement, DJ Pharma was to obtain Dura's rights to Dura-Vent worldwide, and its rights to Rondec and Keftab within the United States. Under the agreement with Schering, DJ Pharma obtained the co-exclusive right to market Cedax in the United States. At the termination of the agreement, all rights to the product revert back to Schering. The products under the license agreements were valued using an income approach, based on the present value of the incremental revenue and corresponding cash flow that could be lost in the absence of these contracts. The discount rate used was an after-tax market-derived rate of 18%. The fair value of the Keftab, Dura-Vent and Rondec products was determined to be $96,500,000, with estimated useful lives of twenty years. The fair value of the Cedax product was determined to be $34,000,000, with an estimated useful life of ten years, based on the remaining term of the Schering agreement.

On December 27, 2000, DJ Pharma and Dura agreed to amend certain provisions of the Dura Agreement, with the effect that the second closing date under the agreement was accelerated from December 31, 2002. Consequently, DJ Pharma obtained the ownership to the Dura-Vent and Rondec product lines, including the trademarks, regulatory history, formulations, manufacturing know-how and marketing information, and the assignment of Dura's license rights to the Keftab product line, as of the amendment date. In consideration, DJ Pharma agreed to make the maximum remaining license payments under the Dura Agreement, and to settle the promissory note payable and the product acquisition notes payable to Dura, plus accrued interest to the amendment date. The remaining maximum license payments amounted to $19,800,000 and have been capitalized to product rights, and the settlement of the principal plus interest due under the notes amounted to $28,100,000.

In 2001, the Company recorded a write-down in the net book values of the Keftab and Dura-Vent product rights as described in note 17 — Write-Down of Assets.

DJ Pharma initiated an Executive Deferred Compensation Plan to provide certain employees with the opportunity to supplement their retirement income through the deferral of pre-tax income. The initial funding of the plan was through compensation deferrals by the plan participants. Those funds, totalling $8,268,000, were placed in trust and invested to purchase life insurance policies (recorded at the cash surrender value) in the names of each participant. The terms of the trust agreement state that the assets of the trust are available to satisfy the claims of general creditors of the company in the event of bankruptcy, thereby qualifying the trust as a rabbi trust for income tax purposes. In accordance with Emerging Issues Task Force Issue 97-14, "Accounting for Deferred Compensation Arrangements Where Amounts Earned Are Held in a Rabbi Trust and Invested", the assets of the trust have been consolidated with the accounts of the employer in the financial statements of the employer, with a corresponding amount recorded as a deferred compensation obligation. Changes in the value of the assets held by the trust are recorded in net income (loss) each period, with a corresponding charge (or credit) to compensation expense, to reflect the fair value of the amount owed to the participants.

The following unaudited pro forma information presents a summary of the consolidated results of operations of the Company and DJ Pharma as if the acquisition had occurred on January 1, 1999. A full year of amortization is included in the consolidated results of both periods presented.

	2000		1999
Total revenue	$	341,382		$	209,645
Net loss		(158,081	)		(114,208	)
Basic and diluted loss per share		(1.23	)		(1.11	)

These unaudited pro forma consolidated results have been prepared for comparative purposes only. They do not purport to be indicative of the results of operations which actually would have resulted had DJ Pharma been included in the Company's consolidated financial statements from January 1, 1999. In addition, they do not purport to be indicative of future consolidated results of operations of the Company.

On November 12, 1999, the Company completed the acquisition of Fuisz Technologies Ltd. ("Fuisz") for $171,154,000 including costs relating to the acquisition. Fuisz is an international company that is engaged in the development, manufacturing and commercialization of a wide range of drug delivery, nutraceutical and food ingredient products utilizing its proprietary CEFORM®, Shearform® and other drug delivery technologies (the "Fuisz Technology").

Fuisz was acquired through a series of transactions which began in July 1999 with the purchase of certain Fuisz common stock and the announcement on July 25, 1999 that the Company had entered into a merger agreement to acquire the remaining common stock of Fuisz in a two-stage transaction consisting of a cash tender offer and a stock-for-stock merger.

By September 4, 1999, the Company had completed the acquisition of 49% of Fuisz's outstanding common stock for cash consideration of $75,565,000 pursuant to the cash tender offer and other purchase transactions. On November 12, 1999, Biovail acquired the remaining common stock of Fuisz by issuing 6,176,620 common shares, with a fair value of $88,243,000. The value of the common shares issued by the Company was determined by reference to the average market price of the Company's common shares before and after the date of the merger agreement on July 25, 1999.

The Company accounted for the acquisition of Fuisz as a step acquisition using the purchase method of accounting. The Company has recognized in these consolidated financial statements its 49% equity interest in the results of Fuisz for the period from September 4, 1999, the date it acquired significant influence, to November 12, 1999, the date of acquisition of control. The equity loss for this period amounted to $58,399,000, and included the Company's proportionate share of acquired research and development. The assets, liabilities, revenues and expenses of Fuisz have been included in these consolidated financial statements from November 12, 1999.

The purchase price of $171,154,000, which includes acquisition costs of $7,346,000, was allocated as follows:

Included in the provision for restructuring costs related to the acquisition of Fuisz, established by the Company at the date of acquisition, was a $10,000,000 reserve for the settlement of a pre-acquisition contract. The settlement of this contract was a contingency that existed prior to the acquisition of Fuisz, and the amount of the reserve was based on the information available to the Company at that time in accordance with SFAS No. 38, "Accounting for Preacquisition Contingencies of Purchased Enterprises". The reserve was included in the determination of the net assets of Fuisz acquired. During 2000, the Company entered into a final settlement of this preacquisition contract. Also during 2000, the Company issued 27,000 additional common shares in relation to the acquisition of Fuisz with a fair value of $386,000. The cash settlement of the contract and the issuance of additional common shares resulted in an additional amount of $7,460,000 that has been allocated to goodwill acquired.

The Fuisz Technology involves drug delivery platforms and the application of such platforms to specific product development programs. At the date of acquisition, Fuisz was involved in seventeen product development projects for a number of pharmaceutical companies which were in various stages of completion. With the exception of certain nutraceutical products, the Fuisz Technology had not been employed in any product which had received regulatory approval to date and was considered to have no alternative future use other than for the therapeutic indications for which it was in development or which may be developed. Accordingly, technological feasibility of the products related to the Fuisz Technology was not established at the acquisition date and was considered to be in-process research and development.

Two of the projects had been submitted for approval with the applicable regulatory authorities. One project was submitted to the FDA in June 1998 and the other was submitted to the U.K. Medical Control Agency in April 1998. The remaining fifteen projects were expected to be completed in accordance with Fuisz's contractual obligations with the relevant customers over the succeeding eighteen months.

The development projects were estimated to be 65% complete on average, estimated peak sales were approximately $942,000,000 per annum, estimated costs to completion of those products were approximately $9,500,000 and a discount rate of 28% was used. The average time to full completion of the remaining work for the projects in development was estimated to be approximately twelve months. The work remaining to complete the products in development involved ongoing formulation, bioequiva-lency, safety and efficacy studies and the submission of regulatory filings to seek marketing approvals. The principal risks relating to the acquired technology were the outcomes of such clinical trials and Biovail's ability to negotiate acceptable commercial terms with the pharmaceutical companies developing the products. As pharmaceutical products cannot be marketed without regulatory approvals, the Company will not receive any benefits unless regulatory approval is obtained.

In 2000, one of the products under development at the acquisition date received approvals for marketing in the United Kingdom and Australia. The product, a rapid dissolve form of ibuprofen, represented the first commercial introduction of a product utilizing the Fuisz Technology. Subsequently, Biovail terminated substantially all of the developmental projects Fuisz had been working on and re-directed the developmental efforts of that organization to formulating a specific number of FlashDose® products targeting Biovail's therapeutic areas of focus. These new Biovail programs utilize some or all of the Fuisz Technology.

The Company determined, as part of its evaluation of the purchase of Fuisz, that certain operations of Fuisz were not strategic to Biovail's business plans and accordingly should be sold.

Prior to the completion of the stock exchange, on October 22, 1999, Fuisz agreed to sell all of the issued shares of three of its wholly-owned European subsidiaries for proceeds of $28,700,000. Further, Fuisz agreed to assign all of the rights, privileges and advantages from its Cebutid trademark to the purchaser of its European subsidiaries for proceeds of $10,273,000. No gain or loss was recognized by the Company on these transactions

as these subsidiaries were included in the purchase price allocation at their fair value when Biovail acquired its 49% interest in Fuisz.

On December 1, 1999, with an effective date of January 4, 2000, the Company entered into an agreement to sell all of the issued share capital of Clonmel Healthcare Limited ("Clonmel"), a pharmaceutical and antibiotic manufacturer and distributor located in Ireland, for proceeds of $20,000,000. The Company recognized no gain or loss on this transaction as Clonmel was included at its fair value in the purchase price allocation at November 12, 1999.

The Company invests its excess cash in high quality (investment grade 'AA' or better) government and corporate debt securities.

The Company performs ongoing credit evaluations of customers and generally does not require collateral. Allowances are maintained for potential credit losses. Three customers accounted for 51% and 61% of trade and royalties receivable at December 31, 2001 and 2000, respectively. The Company believes that there is no unusual exposure associated with the collection of these receivables.

At December 31, 2001 and 2000, the cost of property, plant and equipment included $24,701,000 and $1,676,000, respectively, of assets under construction, or awaiting FDA approval, and not available for productive use. Interest capitalized amounted to $1,089,000 in 2001, and nil in 2000 and 1999.

Depreciation expense amounted to $9,386,000, $8,096,000 and $4,138,000 in 2001, 2000 and 1999, respectively.

Amortization expense amounted to $5,583,000, $2,850,000 and $2,018,000 in 2001, 2000 and 1999, respectively.

Amortization expense amounted to $40,318,000, $10,042,000 and $2,031,000 in 2001, 2000 and 1999, respectively.

On October 4, 1999, Biovail and Elan Corporation, plc ("Elan") entered into a licensing and supply agreement whereby Biovail obtained a license to distribute Elan's generic version of Adalat CC, 30mg dosage ("Adalat"), in exchange for royalties based upon a percentage of sales. The Company first launched Adalat in March 2000. Elan manufactures and supplies Adalat to Biovail.

On December 29, 2000, Biovail and Elan agreed to certain amendments to the licensing and supply agreement (the "Amended Agreement"). The initial term of the Amended Agreement is fifteen years from the date of first commercial sale. Under the terms of the Amended Agreement, Biovail will pay to Elan annual minimum license payments, exclusive of the direct manufacturing cost of Adalat purchased from Elan.

The minimum license payments were capitalized as a product right, with a corresponding long-term obligation to Elan. In accordance with APB No. 21, the value assigned to the product right and obligation was the present value of the minimum license payments based on an imputed interest rate of approximately 8%, which was comparable to the Company's available borrowing rate as at the date of the transaction. Accordingly, the present value of the minimum license payments was determined to be $64,720,000 resulting in a discount of $8,780,000. The product right will be amortized over its estimated useful life, which is the remaining initial term of the Amended Agreement. At the end of the initial term, the Amended Agreement continues automatically for subsequent two-year periods, unless terminated by either party.

Under the terms of the Amended Agreement, Biovail was entitled to recover $15,000,000 in the form of a 50% reduction of the minimum license payments otherwise payable to Elan. During 2001, this amount was recorded as proceeds on reduction in intangible assets.

If in any one or more of the calendar years 2005 to 2009 sales of Adalat are in excess of the amounts prescribed in the Amended Agreement, Biovail will pay to Elan a prescribed percentage of the amount by which the sales of Adalat for that year exceeds the corresponding prescribed amount.

At December 31, 2001, the provision for restructuring costs was comprised of $227,000 (2000 — $1,602,000) related to the acquisition of DJ Pharma, and $1,000,000 (2000 — $1,880,000) related to the acquisition of Fuisz. These costs were included in the determination of the net assets of DJ Pharma and Fuisz acquired. The reduction in the provision was the result of cash payments made during 2001.

At December 31, 2001, up-front research and development fees included $11,500,000 (2000 — nil) in fees received from GSK and $6,689,000 (2000 — nil) in fees received from a privately owned developer as described in note 25 — Research and Development Arrangements.

Interest expense on long-term obligations amounted to $20,195,000, $3,059,000 and $13,594,000 for the years ended December 31, 2001, 2000 and 1999, respectively. Interest expense in 2001 included an amount of $10,999,000 related to the amortization of the discounts on the Adalat and Cardizem® obligations.

Principal repayments on long-term obligations for the years ending December 31 are as follows:

The Company issued under an indenture dated March 22, 2000 (the "Indenture"), 6,000,000 Convertible Subordinated Preferred Equivalent Debentures, due on March 31, 2025 (the "Debentures") for gross proceeds of $300,000,000. After deducting financing costs of $11,228,000, the net proceeds from the issue amounted to $288,772,000. The Debentures were unsecured and subordinated to all senior indebtedness, as defined, of the Company. At the holders' option, the Debentures were convertible at any time into common shares of the Company at $30.337 per common share. During 2000, Debentures of $15,000 aggregate principal amount were converted into 494 common shares of the Company.

At December 31, 2000, the fair value of the Debentures, based on the quoted market price, was $428,979,000.

During 2001, the Company entered into privately negotiated agreements with certain holders of the Debentures. These agreements provided for the issuance of 6,278,663 common shares to those certain Debenture holders upon their surrender of $173,845,000 aggregate principal amount of outstanding Debentures. The Company recorded a debt conversion premium of $23,682,000, which represented the market value of the additional shares issued in excess of the number of shares that would have been issued under the terms of the conversion ratio provided for in the Indenture.

The Company recorded an increase to common shares of $192,623,000, which included the debt conversion premium combined with the carrying value of the Debentures on the date of surrender of $168,941,000. The

carrying value of the Debentures was comprised of the aggregate principal amount of the Debentures plus accrued and unpaid interest to the date of surrender of $1,250,000, reduced by the proportionate unamortized deferred financing costs related to the Debentures of $6,154,000.

In October 2001, the Company announced its intention to exercise its option to redeem the remaining $126,140,000 aggregate principal amount of Debentures on November 27, 2001 (the "Redemption Date") under the terms of the special redemption provisions of the Indenture. Accordingly, holders were entitled to receive a cash payment of $53.375 for each $50 Debenture plus accrued and unpaid interest to the Redemption Date. Holders were also entitled to receive an additional cash payment equal to the present value of the aggregate amount of interest that would have been paid on the Debentures from the Redemption Date to March 31, 2003 (the "Additional Payment"). The Additional Payment was payable on all the Debentures called for redemption whether or not those Debentures were converted into common shares of the Company prior to the Redemption Date. Accrued and unpaid interest at the Redemption Date plus the Additional Payment amounted to $4.98 for each Debenture.

Prior to the Redemption Date, substantially all of the remaining Debentures were converted into 4,154,564 common shares of the Company. The Company recorded a debt conversion premium of $11,241,000, which represented the aggregate Additional Payment.

The Company recorded an increase to common shares of $121,636,000 comprised of the aggregate principal amount of the remaining Debentures, reduced by $108,000 aggregate principal amount of Debentures redeemed for cash on the Redemption Date, and the proportionate unamortized deferred financing costs related to the Debentures of $4,396,000.

The Debentures bore interest at 6.75%, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Interest expense on the Debentures amounted to $14,862,000 and $15,750,000 in 2001 and 2000, respectively.

In October 2000, pursuant to shareholders' consent received at the 2000 annual meeting, the Company's common shares split on a 2 for 1 basis.

In December 1999, the shareholders of the Company authorized a 2 for 1 stock split, and an increase in authorized shares to an unlimited number of common shares without par value.

ll share and per share amounts in these consolidated financial statements have been retroactively adjusted to give effect to the stock splits.

In November 2001, the Company completed a share offering by issuing 12,500,000 common shares for gross proceeds of $587,500,000 less issue costs of $27,454,000.

In March 2000, concurrent with the offering of the Debentures, the Company completed a share offering by issuing 4,000,000

common shares for gross proceeds of $101,125,000 less issue costs of $5,782,000.

In October 1999, the Company completed a share offering by issuing 20,360,000 common shares for gross proceeds of $259,590,000 less issue costs of $13,538,000.

In September 2001, by resolution of the Board of Directors, the Company implemented a common share repurchase program pursuant to which the Company was able to repurchase up to $120,000,000 of its issued and outstanding common shares. In total, 2,871,200 common shares were repurchased under this program, through open market transactions on the NYSE, at an average purchase price of $41.79 for total consideration of $119,987,000. The excess of the cost of the common shares acquired over the stated capital thereof, totalling $105,633,000, was charged to the deficit.

During 1998, the Company implemented a stock repurchase program under which the Company was able to purchase up to 10% of its issued and outstanding common shares. During 1999, 2,930,800 common shares were repurchased at a cost of $30,593,000. The excess of the cost of the common shares acquired over the stated capital thereof, totalling $29,976,000, was charged to the deficit.

Under the Company's Stock Option Plan, as amended (the "Plan"), the Company may grant to directors, officers, employees, consultants and advisors, options to purchase common shares of the Company. The purpose of the Plan is to provide long-term incentives and rewards to the Company's directors, officers, employees, consultants and advisors. The aggregate number of shares reserved for issuance under the Plan, taking into consideration the 2 for 1 stock splits completed in October 2000 and December 1999, shall not exceed 28,000,000 common shares. The number of shares reserved for issuance to any one person under the Plan, together with

shares which that person may acquire under any similar plan of the Company, may not exceed 5% of the total issued and outstanding common shares. Under the Plan, the Company designates the maximum number of shares that are subject to an option. The exercise price per share of an option is the closing market price at which the common shares are traded on the NYSE on the day prior to the date the option is granted, or if not so traded, the average between the closing bid and ask prices thereof as reported for that day.

The options' vesting terms vary based on the type of options. Management options granted prior to January 1, 1999 vest as to one-third each year commencing on the first anniversary of the grant and will expire on a date not later than five years from the date of the grant.

Options granted after January 1, 1999 vest as follows: Executive options vest pursuant to the terms and conditions of the employment agreement; special options vest on the second anniversary date of the grant; management options vest as to one-fourth each year commencing on March 1st and expire not later than seven years from the date of the grant.

The following table summarizes the Company's stock option activity for the three years ended December 31, 2001 taking into effect the 2 for 1 stock splits in October 2000 and December 1999:

The following table summarizes information about options outstanding at December 31, 2001:

(i) These options represent the converted DJ Pharma unvested employee stock options pursuant to the merger agreement as described in note 4 — Acquisitions.

The Company accounts for compensation expense for members of the Plan under the provisions of APB No. 25. Had compensation cost for the Plan been determined based upon the fair value at the grant date for awards under this plan consistent with the methodology prescribed under SFAS No. 123, the Company's net income (loss) and earnings (loss) per share would have changed to the pro forma amounts indicated below:

The fair values of all options granted during 2001, 2000 and 1999 were estimated as of the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

	2001	2000	1999
Expected option life (years)	4.0	4.2	3.8
Volatility	36.9%	41.1%	49.1%
Risk-free interest rate	5.2%	5.8%	5.7%

The Black-Scholes model, used by the Company to calculate option values, as well as other currently accepted option valuation models, were developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differ from the Company's stock option awards. These models also require highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values. Accordingly, management believes that these models do not necessarily provide a reliable single measure of the fair value of the Company's stock option awards.

The Company's Employee Stock Purchase Plan ("EPP") was approved by the shareholders at the Special Shareholders' Meeting held on January 1, 1996 and was established in 1996. The purpose of the EPP is to provide a convenient method for full-time employees of the Company to participate in the share ownership of the Company or to increase their share ownership in the Company via payroll or contractual deduction. Directors, senior officers or insiders of the Company are not eligible to participate in the EPP. The aggregate number of shares reserved for issuance under the EPP, taking into consideration the 2 for 1 stock splits in December 1999 and October 2000, shall not exceed 1,200,000 common shares. At the discretion of a committee of the Board of Directors that administers the EPP, the Company may issue directly from treasury or purchase shares in the market from time to time to satisfy the obligations under the EPP. A participant may authorize payroll or contractual deduction up to a maximum of 10% of the base salary or remuneration to be received during any purchase period. The purchase price shall be 90% of the fair market value per share of stock on the date on which the eligible period ends.

In September 2001, the Board of Directors of the Company authorized the making of loans to certain of its executive officers in order to finance the acquisition of common shares of the Company on the open market pursuant to the Company's Executive Stock Purchase Plan ("ESPP"). During October 2001, the Company made loans in an aggregate amount of $9,988,000 to those certain executive officers under the ESPP. These loans are full recourse and are secured by the common shares purchased pursuant to these loans and bear interest at a rate equal to the Company's rate for borrowings. Interest is payable quarterly in arrears. Each loan is due on the

earlier of: (a) September 30, 2003; (b) 30 days following the termination or cessation of the executive officer's employment with the Company; or (c) where the executive officer disposes of common shares of the Company with a value equal to, or greater than, the loan.

In October 1997, Intelligent Polymers completed a public offering of 3,737,500 units. Each unit comprised one common share of Intelligent Polymers and one warrant to purchase four post-split common shares of the Company. On September 30, 1999, the units separated and Intelligent Polymers' common shares and the Company's warrants traded independently of each other. The warrants are exercisable at a per share price of $10.00 from October 1, 1999 until September 30, 2002.

During 2001, the Company issued 27,600 common shares for proceeds of $276,000 on the exercise of 6,900 warrants. In addition, the Company entered into privately negotiated agreements with certain holders of its outstanding warrants. These agreements provided for the exercise of 758,300 warrants to purchase 3,033,200 common shares. As an inducement to those certain warrant holders to exercise, the Company paid such warrant holders approximately $2 per warrant exercised. In aggregate, the Company received proceeds of $28,817,000 net of the inducement cost of $1,515,000.

During 2000, the Company issued 601,000 common shares for proceeds of $6,010,000 on the exercise of 150,250 warrants.

At December 31, 2001, 2,822,050 (2000 — 3,587,250) warrants to purchase 11,288,200 (2000 — 14,349,000) common shares were outstanding.

In 2001, the Company recorded an $80,482,000 non-cash charge related to the write-down of the following assets:

On March 7, 2001, Eli Lilly announced a voluntary recall of Keftab tablets due to problems with the product's stability. Eli Lilly is under contract with the Company to manufacture and supply the product to the Company for marketing in the United States. At December 31, 2001, the product's manufacturing problems had yet to be resolved by Eli Lilly. The supply interruption has resulted in a deterioration of customer awareness of the product, which would require substantial promotional efforts to restore when, and if, the product were to be re-launched. Due to these conditions that existed at December 31, 2001, the Company determined that the Keftab product right had been permanently impaired and the net book value should be written-down to the estimated recoverable value of $10,000,000. The Company recorded a related non-cash charge of $54,565,000.

The Company believes Eli Lilly is responsible for manufacturing and supplying acceptable products to Biovail, as well as for the cost of the recall. In this regard, the Company has commenced a legal action against Eli Lilly in which Biovail is seeking substantial damages as a result of Eli Lilly's voluntary recall of Keftab. The

Company has not recorded any contingent amounts related to this action because it cannot ascertain what the outcome of this action will be.

In November 2000, the FDA requested a voluntary recall of products containing phenylpropanolamine ("PPA"). The Company immediately stopped shipments of its Dura-Vent products containing PPA and initiated a recall of these products from wholesalers and pharmacies. During 2001, the Company experienced supply interruptions resulting from manufacturing issues associated with its remaining Dura-Vent products that did not contain PPA. Dura-Vent is manufactured and supplied to the Company by a third party. These supply interruptions have caused the Company's revenue and gross margin for the remaining Dura-Vent products to significantly deteriorate. The Company evaluated the current and forecasted market share for the products and determined that the Dura-Vent product right had been permanently impaired and the remaining net book value should be written-off. The Company recorded a related non-cash charge of $18,966,000.

The Company determined that the intangible asset associated with the acquisition of Intelligent Polymers was no longer necessary to its development efforts and the remaining value of the intangible asset should be written-off. The Company recorded a related non-cash charge of $4,000,000.

The Company recorded other write-downs of intangible assets and the investment in Hemispherx totalling $2,951,000.

The reported provision for income taxes differs from the expected amount calculated by applying the Company's Canadian statutory rate to income (loss) before provision for income taxes. The reasons for this difference and the related tax effects are as follows:

The Company has provided for foreign withholding taxes on the portion of undistributed earnings of foreign subsidiaries expected to be remitted.

Deferred income taxes have been provided on the following temporary differences:

In accordance with SFAS No. 109, at the date of acquisition of DJ Pharma the Company recognized deferred tax liabilities of $33,903,000 and deferred tax assets of $1,011,000 for the tax consequences of differences between the assigned values and tax bases of DJ Pharma's acquired assets and liabilities, excluding goodwill. The Company also recognized the available tax benefit of previously existing U.S. federal tax loss carryforwards, through a $32,892,000 reduction in the valuation allowance, an amount equal to the net taxable temporary differences of DJ Pharma. During 2001 and 2000, the Company utilized $1,450,000 and $3,750,000, respectively, of pre-acquisition U.S. federal tax loss carryforwards of Fuisz to reduce taxes on income earned by DJ Pharma since the date of acquisition. The utilization of these loss carryforwards resulted in a corresponding reduction in the value of the Fuisz goodwill acquired.

At December 31, 2001, the Company has accumulated tax losses of approximately $30,100,000 available for federal and approximately $42,400,000 available for provincial purposes in Canada, which expire from 2004 to 2008. The Company also has approximately $12,800,000 of unclaimed Canadian investment tax credits, which expire from 2003 to 2011. The losses and investment tax credits can be used to offset future years' taxable income.

The Company has accumulated tax losses of approximately $77,800,000 for federal and state purposes in the United States, which expire from 2012 to 2021. The losses can be used to offset future years' taxable income.

There may be limitations on the annual utilization of the U.S. net operating losses as a result of certain changes in ownership that have occurred.

In addition, the Company has pooled SR&ED expenditures amounting to approximately $46,100,000 available to offset against future years' taxable income from the Canadian operations, which may be carried forward indefinitely.

In March 2000, the Company repurchased all of its outstanding 10⁷/8% U.S. Dollar Senior Notes due on November 15, 2005 (the "Senior Notes") at a redemption price of 112.820% of the principal amount, plus accrued interest. The aggregate consideration paid to repurchase the Senior Notes was $141,017,000. In accordance with SFAS No. 4, "Reporting Gains and Losses From Extinguishment of Debt", the premium paid of $16,017,000 together with the unamortized deferred financing costs on the Senior Notes of $4,022,000, are reported as an extraordinary item in the consolidated statements of income (loss).

In accordance with SFAS No. 128, "Earnings per Share", earnings per share are computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the reporting period. Earnings (loss) per share, for all periods presented, were calculated using the weighted average number of common shares outstanding during the year, as follows:

For 2000 and 1999, all warrants and stock options were excluded from the calculation of diluted loss per share because the effect would have been anti-dilutive. For all periods presented, the potential dilutive effect of warrants and stock options on the weighted average number of common shares outstanding was as follows:

For 2001 and 2000, the Debentures have been excluded from the calculation of diluted loss per share because the effect would have been anti-dilutive.

The Company occupies certain facilities under lease arrangements and leases certain equipment. Rental payments amounted to approximately $5,200,000, $4,800,000 and $700,000 in 2001, 2000 and 1999, respectively.

Future minimum lease payments under operating leases for the years ending December 31 are as follows:


2002	$	4,973
2003		2,644
2004		2,482
2005		1,748
2006		1,134
Thereafter		2,299

In June 2001, the Company acquired a corporate aircraft from an entity controlled by the Chairman of the Company's Board of Directors for cash consideration of $10,475,000. The exchange amount was established based on comparable market prices for the aircraft at the time of acquisition.

In March 2001, the Company loaned $600,000 to one of its executive officers. The loan is secured by a charge on the officer's personal residence. The loan does not bear interest until March 1, 2004 and thereafter bears interest at a rate equal to the Company's rate of borrowing. The loan is due on the earlier of termination of employment or March 31, 2008.

From time to time, the Company becomes involved in various legal proceedings which it considers to be in the ordinary course of business. The vast majority of these proceedings involve intellectual property issues that often result in patent infringement suits brought by patent holders upon the filing of ANDA applications. The timing of these actions is mandated by statute and may result in a delay of FDA approval for such filed ANDAs until the final resolution of such actions or the expiry of 30 months, whichever occurs earlier. There are also

ordinary course employment dismissal and related issues and claims in which the Company routinely becomes involved but which individually and collectively are not material.

The Company has been sued in separate lawsuits by Bayer AG and Bayer Corporation (collectively "Bayer"), as well as by Pfizer Inc. ("Pfizer"), upon the filing by Biovail of separate ANDAs for generic versions of Procardia XL and Adalat CC. These actions make the usual, technical claims of infringement. Biovail is vigorously defending these suits and is aggressively pursuing motions for summary judgment. Biovail has denied the allegations and has pleaded affirmative defenses that the patents are invalid, have not been infringed and are unenforceable. Biovail believes that Bayer/Pfizer's claims are without merit.

On April 23, 1998, Biovail filed a four-count complaint against Bayer and Pfizer seeking a declaratory judgment that their patent is invalid, unenforceable, and not infringed by our filing of the ANDAs. Biovail has also asserted that Bayer and Pfizer have violated anti-trust laws and have interfered with Biovail's prospective economic advantage. Biovail's action has been stayed until the conclusion of the patent infringement suits.

In February, 2001, Biovail commenced an action against Mylan Pharmaceuticals, Inc. ("Mylan") and Pfizer claiming damages resulting from an agreement between Mylan and Pfizer that had the effect of blocking the timely marketing of Biovail's generic version of Pfizer's 30 mg Procardia XL. Biovail's action alleges that in entering into, and implementing, such agreement Mylan and Pfizer contravened various statutory provisions and common law obligations. While Biovail believes its action is meritorious, nevertheless, it is not possible, at this early stage, to determine the quantum of damages that may be the subject of an award.

Biovail has commenced an action against Mylan with respect to Mylan's breach of contract relating to its supply product obligations to the Company. Biovail believes that it has a meritorious action and that it will recover damages consisting of lost sales.

The Company has commenced an action against Eli Lilly and Company ("Lilly") in which Biovail is seeking substantial damages as a result of Lilly's voluntary recall of Biovail's product Keftab. Lilly is under contract with Biovail to manufacture and supply the product to Biovail for marketing in the United States. Lilly has forced a recall of the product because it has been unable to supply a stable product. Biovail believes its claims against Lilly for damages it has suffered as a result of the Keftab recall are meritorious and is proceeding in its legal action to pursue those claims with dispatch.

A plaintiff recently commenced an action against Biovail Pharmaceuticals, Inc. ("BPI") alleging personal injuries arising from her use of Duravent, a product currently being marketed by BPI. We believe that this claim is without merit and, in the event the case proceeds further, it will be vigorously defended.

On or about February 15, 2001, Andrx Pharmaceuticals, Inc. ("Andrx") commenced action against Biovail in which Andrx alleged that Biovail had improperly listed a patent (No. 6,162,463) in the FDA's "Orange Book" and sought declaratory and injunctive relief including a de-listing of the patent, and alleged further that in listing such patent, Biovail had violated certain statutes and the common law. Andrx' motion for injunctive relief was denied. Biovail has asserted defenses which it believes are meritorious. Biovail has launched a patent infringement action against Andrx in which Biovail has claimed that Andrx' product infringes Dov Pharmaceutical's '463 Patent over which Biovail has exclusive patent rights. This action has been proceeding

through the normal litigation channels. Nevertheless, the Company and Andrx have entered into a Letter Agreement which, if finalized, would result in an overall settlement of a number of disputes between them.

Biovail and Andrx are currently negotiating a definitive Agreement pursuant to the Letter Agreement, but it is premature to say whether a final Agreement will be completed.

The Federal Trade Commission ("FTC") has been conducting investigations relating generally to the introduction of generic products, and more specifically with respect to the proposed introduction of generic versions of Tiazac and Adalat CC. Biovail has been engaged in cooperating with the FTC and in providing information to it to demonstrate that the Company's actions have been proper and in compliance with the law. Biovail has recently settled with the FTC through a Consent Decree (without any admission of impropriety) the issues with respect to the FTC's investigation into the introduction of a generic version of Tiazac. As a result of the Consent Decree with the FTC, the Company has discontinued its patent infringement case with respect to the '463 Patent. The Company has also de-listed the '463 patent from the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations". The FTC's other investigation relating to the introduction of generic versions of Adalat CC is continuing and, while the FTC staff have made an initial recommendation to proceed against the Company with an administrative proceeding, the Company is continuing to provide information to the FTC and plans to make formal submissions to the individual Commissioners to demonstrate that the Company's actions were, and are, proper.

Several class action Complaints have been filed against the Company in which these Plaintiffs have alleged that the Company has improperly impeded the approval of a generic form of Tiazac. The Company has not yet filed an Answer but it believes that the Complaints are totally without merit and that the Company's actions were in accord with its rights as contained in the Hatch-Waxman Amendments and the law. Moreover, the Company's position that none of its actions was responsible for the inability of that product to receive final marketing approval by the FDA. The Company will be vigorously defending these actions.

RhoxalPharma Inc. has filed an abbreviated new drug submission ("ANDS") in Canada, seeking approval of a generic version of Tiazac. In an attempt to comply with the Patented Medicines (Notice of Compliance) Regulations, RhoxalPharma has alleged to Health Canada that Canadian Patent No. 2,111,085, of which Biovail is the exclusive licensee, would not be infringed by the sale in Canada of RhoxalPharma's generic version of Tiazac. RhoxalPharma served a notice of that allegation on Biovail. In response to that notice, Biovail instituted proceedings in the Federal Court of Canada in March 2002 to prohibit the issue of a Notice of Compliance (which is needed before RhoxalPharma can market its product in Canada) to RhoxalPharma until the merits of RhoxalPharma's allegations can be determined by the Federal Court. Until those proceedings are concluded, or until the expiry of 24 months after March 2002, whichever is earlier, no Notice of Compliance will be issued to RhoxalPharma.

A Certificate of Non-Infringement was served by Torpharm, Inc. ("Torpharm") on Aventis Pharmaceuticals Inc. ("Aventis") in respect of its filed ANDA of a generic version of Cardizem® CD (120mg, 180mg and 300mg) with the FDA. The patents against which Torpharm certified were acquired by Biovail Laboratories Incorporated ("BLI") as part of BLI's acquisition of the Cardizem® family of products. BLI has determined that Torpharm's ANDA infringes BLI's patents and a legal suit has been commenced against Torpharm, the effect of which was to trigger the Hatch-Waxman provisions. As a result, the FDA is statutorily

and automatically precluded from granting approval to Torpharm until the earlier of 30 months after the filing of the legal suit, a final court decision of non-infringement or patent invalidity or a court's decision to abbreviate the 30-month stay.

In the ordinary course of business, the Company enters into research and development arrangements with third parties to provide formulation and other services for its products under development. These third party developers are typically compensated on the basis of a fee for service, milestone payments or royalty payments from the future sale of the products under development, or some combination of these. In addition, in the ordinary course of business the Company enters into research and development arrangements with third parties whereby the Company provides contract research, formulation development and other services to those third parties. The Company is typically compensated on the basis of a fee for service, milestone payments, royalties from future sales of the product(s) or co-promotion revenue, or some combination of these. The Company recorded research and development revenue from third parties of $14,596,000, $66,834,000 and $48,232,000 in 2001, 2000 and 1999 respectively. The cost of providing these services to these third parties was $7,596,000, $41,522,000 and $27,462,000 in 2001, 2000 and 1999, respectively.

On October 26, 2001, Biovail and GSK entered into a development and co-promotion agreement for bupropion hydrochloride ("HCl"). Under the terms of the agreement, Biovail has licensed to GSK a novel controlled-release, once-daily formulation of bupro-pion HCl ("Wellbutrin Once Daily") for sale and distribution on a worldwide basis excluding Canada. Bupropion HCl, which is marketed for the treatment of depression as Wellbutrin by GSK, is currently sold in sustained-release ("SR"), twice-daily, and immediate-release ("IR"), four-times daily, dosage formats. Under the terms of the Wellbutrin Once Daily agreement, Biovail and GSK will collaborate to direct regulatory and scientific development to seek regulatory approval of Wellbutrin Once Daily. GSK and Biovail intend to file a New Drug Application ("NDA") for Wellbutrin Once Daily with the FDA during mid-2002. When and if FDA approval is received, Biovail will manufacture and supply Wellbutrin Once Daily to GSK for a share of the revenue generated by future sales of Wellbutrin Once Daily. GSK and Biovail will co-promote Wellbutrin SR and Biovail will have the option to co-promote Wellbutrin Once Daily in the United States when and if FDA approval is received.

In consideration for the activities undertaken by Biovail under the agreement, GSK will pay Biovail up to $61,500,000 in six quarterly increments starting with the first increment of $11,500,000 payable within 30 days of the receipt of approval under the Hart-Scott-Rodino ("HSR") Act in the United States. The remaining five quarterly increments, of up to $10,000,000 each, will be received in each of the five calendar quarters following GSK's acceptance of the Wellbutrin Once Daily formulation. The receipt of each of the remaining quarterly increments is dependent on Biovail performing prescribed detailing activity, and the amount will be determined based upon a percentage of net sales of Wellbutrin SR in the United States during each quarter.

HSR Act approval was received effective December 7, 2001 and, accordingly, Biovail was entitled to receive the first increment of $11,500,000. At December 31, 2001, this amount has been recorded in deferred revenue and will be recognized as revenue relative to the development and co-promotion services provided.

Either Biovail or GSK may, at its option, terminate the agreement subject to certain conditions. Upon termination of the agreement, each party may retain any amounts paid to them, and shall pay to each other all amounts accrued which are then due. GSK will not be obligated to pay the quarterly increment for any quarter in which termination of the agreement becomes effective or for any quarter thereafter. All rights to Wellbutrin Once Daily granted to GSK will revert to Biovail, and GSK will permit access to all regulatory data and information related to Wellbutrin IR and bupropion HCl, as appropriate, for the sole purpose of enabling Biovail to obtain regulatory approval for Wellbutrin Once Daily.

During 2001, the Company entered into arrangements with unrelated third party formulating and product development companies. These arrangements target the Company's therapeutic areas of focus (cardiovascular, pain management, central nervous system and niche opportunities) and typically include formulation and product development services being rendered by the developer in return for payments upon the attainment of predetermined milestones, and royalties on the net sales of the product(s) if and when commercialized. The developer may utilize its own technology and in other cases, the Company will supply access to its technology for the formulation and development of the product(s). In some cases, the Company has an ownership interest or an option to take an ownership position in the developer. In no case is the Company responsible for any of the developers' third party liabilities, nor has the Company guaranteed any debts, nor is the Company required under any circumstances to exercise any of its options.

In 2001, the Company and a developer entered into a research and development arrangement, whereby parties will collaborate on the development of a product targeting one of the Company's stated therapeutic areas of focus. The Company provides contract research services consistent with contractual relationships the Company has with other third parties. If the developer is successful in its product development efforts and if the Company elects to move forward with the program, the Company will fund the clinical trials related to the product and will make milestone payments of up to $10,000,000 to the developer upon the attainment of certain events. Upon the completion of the development of the product, the Company will have the right to manufacture and sell the products developed and the developer will be entitled to royalties from the net sales of the product by the Company.

The Company also entered into a product development agreement whereby another developer will formulate and develop a controlled-release product utilizing the Company's and their own proprietary technologies. The Company will make milestone payments of up to $500,000 to the developer upon the attainment of certain events. Upon the completion of the development of the product, the Company has the right to manufacture and sell the products developed and has an option to enter into a separate manufacturing and supply agreement. If the Company does not exercise its option, then the developer will be entitled to royalties from the net sales of the product by the Company.

The Company has also entered in an agreement whereby a third developer is responsible for the formulation and development of a portfolio of products utilizing the Company's technologies. The developer contracts directly with third parties, and potentially the Company, to conduct the contract research and development services. The Company provides advisory services and contract research services consistent with contractual relationships the Company has with other third parties. Upon the completion of the development of the products, the Company will have the right to manufacture and sell the products and the developer will be entitled to royalties from the net sales of each product by the Company, or its licensees, for a period of ten years

from the launch of each product. The Company has an option to acquire the developer's interest in the products or to acquire the developer. If the Company elects to exercise its option to acquire the entity, the Company would be responsible for the developer's third party liabilities.

In total, the Company earned revenue from providing advisory and contract research services to the developers of $3,448,000 in 2001. The cost of providing these services to the developers was $2,938,000, and the Company incurred other development costs related to these agreements of $2,191,000 and were also reimbursed amounts at cost of $1,395,000 in 2001.

In early 2002, the Company entered into two additional arrangements as described in note 27 — Subsequent Events.

In December 1998, the Company entered into an agreement with H. Lundbeck A/S ("Lundbeck"), for the formulation, development, manufacture and supply of a novel controlled-release formulation of the anti-depressant citalopram.

Under the terms of the agreement, Lundbeck paid the Company product development fees in an aggregate amount of $8,500,000, subject to certain milestones. In 2001, the Company completed the services in respect of the final milestone and received the remaining $2,000,000 product development fee from Lundbeck. The Company received product development fees of $1,000,000 and $2,000,000 in 2000 and 1999, respectively.

In December 1997, the Company entered into an agreement with a subsidiary of Teva Pharmaceuticals USA, Inc. ("Teva") for the development and marketing of certain generic oral controlled-release products. As at December 31, 2001, generic versions of Trental, Cardizem CD, Adalat CC, Voltaren XR and Procardia XL have been approved by the FDA, and ANDAs for two others have been filed with the FDA. Pursuant to a separate agreement, the Company earned $4,800,000 of research and development revenue from Teva in 1999.

Organizationally, the Company's operations consist of three segments: Product Sales, Research and Development, and Royalty and Licensing. The segments are determined based on several factors including customer base, the nature of the product or service provided, delivery channels and other factors.

The Product Sales segment covers sales of production from the Company's Puerto Rican and Canadian manufacturing facilities, and sales of proprietary and in-licensed branded products by the Company's sales and marketing operations.

The Research and Development segment covers all revenue generated by the Company's integrated research and development facilities, and comprises research and development services provided to third parties, including Intelligent Polymers prior to September 29, 2000, and product development milestone fees.

The Royalty and Licensing segment covers royalty revenue received from licensees in respect of products for which the Company has manufacturing, marketing and/or intellectual property rights.

The accounting policies of the segments are the same as those described in the significant accounting policies. The Company evaluates segment performance based on operating income after deducting selling, general and administrative expenses attributable to the business units. Corporate general and administrative expenses, interest income and expense, and debt conversion premiums are not allocated to segments. Depreciation expense related to manufacturing and research and development assets is allocated to the Product Sales and Research and Development segments, respectively. Amortization expense related to royalty interests is allocated to the Royalty and Licensing segment. Amortization expense related to product rights is allocated to the Product Sales segment.

Depreciation and amortization of administrative assets and goodwill are included as a component of unallocated general and administrative expenses. Write-downs of assets are included in segment operating income (loss).

The following table identifies external customers accounting for 10% or more of the Company's total revenue:

The following table identifies the segments reporting the combined revenue from the Company's major customers:

Biovail entered into an agreement with GSK for the exclusive distribution rights for prescription strength Zovirax Ointment and, upon FDA approval, Zovirax Cream, for the United States and Puerto Rico. Zovirax is indicated for the treatment of herpes. Under the terms of the agreement, Biovail paid GSK $133,000,000 on January 2, 2002 for the distribution rights to the Zovirax products effective January 1, 2002 until December 31,

2011. In the event of the termination of the bupropion HCl development agreement by either party, as described in note 25 — Research and Development Arrangements, Biovail would be required to pay GSK additional payments of $22,000,000 per year for calendar years 2002 through 2006, with an aggregative cumulative total of all additional rights payments not to exceed $99,000,000, and for calendar years 2007 through 2011 Biovail would be required to pay GSK additional payments based upon a percentage of Biovail's gross sales of the Zovirax products during the immediately preceding calendar year.

GSK will manufacture and supply Zovirax Ointment, and Zovirax Cream upon FDA approval, to Biovail. Biovail will begin promotional efforts related to Zovirax Ointment in January 2002 and intends to launch Zovirax Cream when and if FDA approval is received. In order to gain FDA approval for Zovirax Cream, GSK will work with the FDA to reinstate an NDA previously filed by GSK for the product. GSK will also conduct a pediatric Phase IV marketing study for Zovirax Cream.

On January 4, 2002, the Company invested approximately $2,500,000 in non-voting, non-participating preferred shares of Procyon Biopharma Inc. ("Procyon"), and acquired the exclusive marketing rights to FIBROSTAT in the United States. FIBROSTAT is a topical therapeutic for scar management. The Company will pay aggregate fees of approximately $5,100,000 to Procyon for the development of FIBROSTAT, subject to the attainment of certain milestones. Upon approval and commercialization of FIBROSTAT in the United States the Company will pay a licensing fee to Procyon of approximately $3,100,000, as well as royalties based upon a percentage of net sales of FIBROSTAT.

The Company may require Procyon to redeem the preferred shares during the period from January 1, 2004 to December 31, 2006. Procyon may elect to redeem the preferred shares for cash or convert them into common shares based upon prescribed conversion terms.

In February 2002, by resolution of the Board of Directors, the Company implemented a common share repurchase program pursuant to which the Company is able to repurchase up to 5% or approximately 7,850,000 of its issued and outstanding common shares. To April 17, 2002, an aggregate 5,657,100 common shares have been repurchased under this program, through open market transactions on the NYSE, at an average purchase price of $46.01 for total consideration of $260,291,000. The excess of the cost of the common shares acquired over the stated capital thereof, totalling $209,717,000, will be charged to the deficit.

On March 18, 2002, Biovail announced that it had acquired from Solvay Pharmaceuticals Marketing and Licensing AG ("Solvay") the exclusive marketing rights for Teveten and Teveten HCT in the United States. Teveten is an angiotensin-II receptor blocker ("ARB") and Teveten HCT is a combination formulation

containing hydrochlorothiazide (collectively "Teveten"). Teveten is prescribed for the treatment of hypertension and is indicated for use either alone or in conjunction with other anti-hypertensive medications. The purchase price for Teveten was $94,000,000 in cash and Biovail will pay royalties to Solvay based upon a percentage of the net sales of Teveten in the United States. Under the terms of the agreement, Solvay will manufacture and supply Teveten to Biovail, and will assist Biovail in qualifying a site to enable Biovail or a third party selected by Biovail to manufacture Teveten for distribution in the United States. Solvay will pay a marketing allowance to Biovail, of $2,500,000 per quarter for each calendar quarter during 2002 and 2003, to compensate Biovail for the re-launch and marketing of Teveten in the United States.

Pursuant to a supplement to its base shelf prospectus, dated March 25, 2002, the Company issued $400,000,000 aggregate principal amount of unsecured 7⁷/8% Senior Subordinated Notes due on April 1, 2010 (the "Notes"). The Notes were issued under an indenture dated March 28, 2002. Interest on the Notes is payable semi-annually in arrears on April 1 and October 1 of each year, beginning October 1, 2002. The Notes were issued at a price of 99.27% of their aggregate principal amount for an effective yield, if held to maturity, of 8%. Proceeds from the issue amounted to $384,280,000, net of discount and financing costs.

At any time on or after April 1, 2006, the Company may redeem all or any of the Notes at the following prices, plus accrued and unpaid interest to the date of redemption, if redeemed during the twelve months beginning April 1 of the years indicated below:

Before April 1, 2005, the Company may redeem up to 35% of the original principal amount of the Notes, with the net cash proceeds of certain sales of the Company's common shares, at 107.875% of the principal amount plus accrued and unpaid interest to the date of redemption.

On April 15, 2002, the Company announced that it entered into multiple agreements with Ethypharm S.A. ("Ethypharm") whereby Biovail has acquired a 15% equity interest in Ethypharm and the right to license six on-going product development programs for marketing in North America. Biovail and Ethypharm have also entered into a cross-license agreement whereby the two companies grant to each other non-exclusive licenses to

use Biovail's CEFORM® technology and Ethypharm's Flashtab technology, respectively, relating to the development of new rapid dissolve pharmaceutical products.

Under the terms of the stock purchase agreement, Biovail has invested approximately $65,000,000 to acquire 15% of the issued and outstanding shares of Ethypharm. Biovail has an option to purchase up to an additional 5% interest in Ethypharm at the same price for a specified period and another 5% interest over a three-year period at predetermined prices. This strategic investment will help finance Ethypharm's growth strategies and gives Biovail access to complementary drug delivery technologies, a strong intellectual property position and access to the pipeline products, several of which are in late stages of development.

Under the terms of the product development and licensing agreement, Biovail has licensed the marketing rights to six products from Ethypharm for commercialization in North America. Ethypharm is entitled to receive up to $61,000,000 in milestone payments upon regulatory approval of the products within the territories as well as royalties on the net sales of the products. Under the terms of the agreement, Ethypharm is committed to accelerate the developmental activities of the six licensed products through completion of Phase III clinical trials and to support the technology transfer required to allow Biovail to efficiently and economically optimize the use of the Ethypharm technology in the manufacture and marketing of each product.

Prior to 2001, the Company included amortization expense as a component of cost of goods sold, research and development expenses, and selling, general and administrative expenses. In 2001, amortization expense increased substantially due to recent additions to intangible assets and acquisitions of businesses, and consequently the Company decided to present amortization as an individual line item within operating expenses. The reclassification of prior years' figures, to reflect the presentation adopted in 2001, did not change the total operating expenses or net operating losses as previously reported.

Certain of the prior years' figures have been reclassified to conform to the presentation adopted in the current year.

TABLE 7-01 SEVEN YEAR FINANCIAL SUMMARY
(All dollar amounts expressed in thousands of U.S. dollars, except per share and share price information)

TABLE 8-01 SELECTED QUARTERLY DATA
(All dollar amounts expressed in thousands of U.S. dollars, except per share and share price data)

BOARD OF DIRECTORS
Eugene N. Melnyk Chairman of the Board and Chief Executive Officer, Biovail Corporation		Paul W. Haddy Chairman and Chief Executive Officer, London Life Bank & Trust Corporation
Rolf K. Reininghaus Senior Vice President, Corporate and Strategic Development, Biovail Corporation		Bruce D. Brydon Director, Biovail Corporation
Roger Rowan President and Chief Operating Officer, Watt Carmichael Inc.		Robert Vujea President, R&D Chemical Corporation
Wilfred Bristow Senior Vice President, Nesbitt Burns Inc.

OFFICERS
Eugene N. Melnyk Chairman of the Board and Chief Executive Officer		William S. Poole President, North American Pharmaceuticals
Brian H. Crombie Senior Vice President and Chief Financial Officer		Kenneth G. Howling Vice President, Finance
Kenneth C. Cancellara, Q.C. Senior Vice President, Corporate Secretary and General Counsel		John R. Miszuk Vice President, Controller and Assistant Secretary
Rolf K. Reininghaus Senior Vice President, Corporate and Strategic Development		Patrick D. Dwyer Vice President, Manufacturing

TABLE 1-01 FINANCIAL HIGHLIGHTS
Years ended December 31
(All dollar amounts expressed in thousands of U.S. dollars, except per share data)

	2001		2000			1999
OPERATING RESULTS
Product sales	$	537,138	$	224,996		$	99,526
Total revenue		583,263		309,170			172,464
Research and development expenses		51,017		51,709			32,954
Operating income (loss)		171,156		(78,032	)		(40,160	)
Net income (loss)		87,448		(147,976	)		(109,978	)
Net income excluding certain charges⁽¹⁾		202,853		123,987			52,162
EBITDA⁽²⁾		306,925		151,380			73,716
Cash flows from operating activities		284,121		102,494			51,985
Diluted per share information
Net income (loss)	$	0.58	$	(1.16	)	$	(1.07	)
Net income excluding certain charges⁽¹⁾		1.35		0.86			0.48
EBITDA⁽²⁾		2.04		1.05			0.68
Cash flows from operating activities		1.89		0.71			0.48
Weighted average number of common shares outstanding (000s)		150,690		143,512			108,174
FINANCIAL POSITION
Cash and cash equivalents	$	434,891	$	125,144		$	178,086
Total assets		1,331,483		1,107,267			467,179
Long-term obligations and Debentures		46,161		738,729			137,504
Shareholders' equity		1,126,074		237,458			267,336
Shareholders' equity excluding certain charges⁽¹⁾		1,671,965		667,944			425,859
RATIOS
EBITDA as a percentage of total revenue⁽²⁾		52.6%		49.0%			42.7%
Net income excluding certain charges as a percentage of total revenue⁽¹⁾		34.8%		40.1%			30.2%
Return on equity excluding certain charges⁽¹⁾		17.3%		22.7%			22.1%
Ratio of EBITDA to interest expense⁽²⁾		8.5X		7.3X			5.1X
Product sales growth		138.7%		126.1%			43.9%
Total revenue growth		88.7%		79.3%			54.5%


FIG 3-06		FIG 3-07
Going forward, Biovail's R&D activities will be more focused on NDA opportunities.		Research and development activities focused on advanced drug delivery systems are conducted at state-of-the-art facilities in the U.S., Canada and Ireland.


FIG 3-08		FIG 3-09
The Company is developing new products to expand its therapeutic focus in cardiology, pain management and CNS.		The Contract Research Division has been expanded to support early clinical trials and bioanalysis for Biovail and independent clients.

													Percentage Change
	Years Ended December 31												Percentage Change
	Years Ended December 31												2000 to 2001		1999 to 2000
	2001				2000				1999				2000 to 2001		1999 to 2000
Cost of goods sold	$	125,995	21	%	$	67,980	22	%	$	35,027	20	%	85%		94%
Research and development		51,017	9			51,709	17			32,954	19		(1%	)	57%
Selling, general and administrative		110,100	19			51,857	17			36,165	21		112%		43%
Amortization		44,513	8			7,232	2			2,789	2		516%		159%

Total expenses		331,625	57			178,778	58			106,935	62		85%		67%

	Years ended December 31
	2001		2000			1999
	(In 000s)
Net income (loss)	$	87,448	$	(147,976	)	$	(109,978	)
Net interest (income) expense		33,500		(2,955	)		9,152
Provision for income taxes		15,285		9,360			4,215
Depreciation and amortization		55,287		20,988			8,187

EBITDA		191,520		(120,583	)		(88,424	)

Write-down of assets		80,482		—			—
Debt conversion premiums		34,923		—			—
Acquired research and development		—		208,424			105,689
Extraordinary item		—		20,039			—
Cumulative effect of change in accounting principle		—		43,500			—
Equity loss		—		—			58,399
Net gain on disposal of long-term investments		—		—			(1,948	)

EBITDA excluding certain charges	$	306,925	$	151,380		$	73,716


EUGENE N. MELNYK Chairman and Chief Executive Officer		BRIAN H. CROMBIE Senior Vice President and Chief Financial Officer

	2001			2000
ASSETS
Current
Cash and cash equivalents	$	434,891		$	125,144
Accounts receivable		96,556			105,850
Inventories		38,506			24,108
Deposits and prepaid expenses		6,643			5,347

		576,596			260,449
Long-term investments		2,355			1,561
Property, plant and equipment, net		85,581			52,541
Goodwill, net		96,477			103,105
Intangible assets, net		556,360			667,431
Other assets, net		14,114			22,180

		1,331,483			1,107,267

LIABILITIES
Current
Accounts payable		31,811			34,683
Accrued liabilities		59,989			35,452
Income taxes payable		17,318			6,711
Deferred revenue		27,030			26,334
Current portion of long-term obligations		12,592			182,564

		148,740			285,744
Deferred revenue		23,100			27,900
Long-term obligations		33,569			256,180
Convertible Subordinated Preferred Equivalent Debentures		—			299,985

		205,409			869,809
SHAREHOLDERS' EQUITY
Common shares, no par value, unlimited shares authorized, 157,496,407 and 131,461,060 issued and outstanding at December 31, 2001 and 2000, respectively		1,407,507			482,842
Stock options outstanding		5,067			9,891
Executive Stock Purchase Plan loans		(9,988	)		—
Warrants outstanding		6,221			7,912
Deficit		(280,004	)		(261,819	)
Accumulated other comprehensive loss		(2,729	)		(1,368	)

		1,126,074			237,458

		1,331,483			1,107,267




EUGENE N. MELNYK Chairman and Chief Executive Officer		ROGER D. ROWAN Director

	2001			2000			1999
REVENUE
Product sales	$	537,138		$	224,996		$	99,526
Research and development		14,596			66,834			48,232
Royalty and licensing		31,529			17,340			24,706

		583,263			309,170			172,464

EXPENSES
Cost of goods sold		125,995			67,980			35,027
Research and development		51,017			51,709			32,954
Selling, general and administrative		110,100			51,857			36,165
Amortization		44,513			7,232			2,789
Write-down of assets		80,482			—			—
Acquired research and development		—			208,424			105,689

		412,107			387,202			212,624

Operating income (loss)		171,156			(78,032	)		(40,160	)
Interest income		2,742			23,693			5,410
Interest expense		(36,242	)		(20,738	)		(14,562	)
Debt conversion premiums		(34,923	)		—			—
Equity loss		—			—			(58,399	)
Gain on disposal of long-term investments, net		—			—			1,948

Income (loss) before provision for income taxes		102,733			(75,077	)		(105,763	)
Provision for income taxes		15,285			9,360			4,215

Income (loss) before extraordinary item and cumulative effect of change in accounting principle		87,448			(84,437	)		(109,978	)
Extraordinary item		—			(20,039	)		—

Income (loss) before cumulative effect of change in accounting principle		87,448			(104,476	)		(109,978	)
Cumulative effect of change in accounting principle		—			(43,500	)		—

Net income (loss)		87,448			(147,976	)		(109,978	)

Basic earnings (loss) per share
Income (loss) before extraordinary item and cumulative effect of change in accounting principle		0.64			(0.66	)		(1.07	)
Extraordinary item		—			(0.16	)		—
Cumulative effect of change in accounting principle		—			(0.34	)		—

Net income (loss)		0.64			(1.16	)		(1.07	)

Diluted earnings (loss) per share
Income (loss) before extraordinary item and cumulative effect of change in accounting principle		0.58			(0.66	)		(1.07	)
Extraordinary item		—			(0.16	)		—
Cumulative effect of change in accounting principle		—			(0.34	)		—

Net income (loss)		0.58			(1.16	)		(1.07	)

Weighted average number of common shares outstanding (000s)
Basic		136,928			128,824			102,542
Diluted		150,690			143,512			108,174

		Common shares
		Common shares				Stock options outstanding		Executive Stock Purchase Plan loans	Warrants outstanding		Warrant subscription receivable		Retained earnings (deficit)		Accumulated other comprehensive income (loss)
		Shares/000s		Amount		Stock options outstanding		Executive Stock Purchase Plan loans	Warrants outstanding		Warrant subscription receivable		Retained earnings (deficit)		Accumulated other comprehensive income (loss)		Total
Balance, December 31, 1998		99,444		21,394		2,560		—	8,244		(6,315	)	26,111		(2,106	)	49,888
Issued on the exercise of options		1,336		8,467		(838	)	—	—		—		—		—		7,629
Issued under Employee Stock Purchase Plan		6		40		—		—	—		—		—		—		40
Cancelled under stock repurchase program		(2,931	)	(617	)	—		—	—		—		(29,976	)	—		(30,593	)
Issued pursuant to equity offering		20,360		259,590		—		—	—		—		—		—		259,590
Issue costs		—		(13,538	)	—		—	—		—		—		—		(13,538	)
Fuisz Technologies Ltd.
	Issued on acquisition	6,177		88,243		—		—	—		—		—		—		88,243
	Issue of non-employee options	—		—		1,020		—	—		—		—		—		1,020
Compensation cost for employee stock options		—		—		7,641		—	—		—		—		—		7,641
Collection of warrant subscription receivable		—		—		—		—	—		4,028		—		—		4,028

		124,392		363,579		10,383		—	8,244		(2,287	)	(3,865	)	(2,106	)	373,948

Net loss		—		—		—		—	—		—		(109,978	)	—		(109,978	)
Other comprehensive income
Foreign currency translation adjustment		—		—		—		—	—		—		—		2,489		2,489
Reclassification adjustment for gain on long-term investments included in net loss		—		—		—		—	—		—		—		877		877

Other comprehensive income		—		—		—		—	—		—		—		3,366		3,366

Comprehensive loss																	(106,612	)

Balance, December 31, 1999		124,392		363,579		10,383		—	8,244		(2,287	)	(113,843	)	1,260		267,336
Issued on the exercise of options		2,436		17,027		(3,302	)	—	—		—		—		—		13,725
Issued under Employee Stock Purchase Plan		5		150		—		—	—		—		—		—		150
Issued pursuant to equity offering		4,000		101,125		—		—	—		—		—		—		101,125
Issue costs		—		(5,782	)	—		—	—		—		—		—		(5,782	)
Issued on conversion of Convertible Subordinated Preferred Equivalent Debentures		—		15		—		—	—		—		—		—		15
Issued on exercise of warrants		601		6,342		—		—	(332	)	—		—		—		6,010
Issue of non-employee options		—		—		590		—	—		—		—		—		590
Additional shares issued on acquisition of Fuisz Technologies Ltd.		27		386		—		—	—		—		—		—		386
DJ Pharma, Inc.
	Fair value of unvested options granted to employees on acquisition	—		—		7,480		—	—		—		—		—		7,480
	Unearned compensation relating to future service period at acquisition date	—		—		(5,721	)	—	—		—		—		—		(5,721	)
	Compensation cost for employee stock options	—		—		461		—	—		—		—		—		461
Collection of warrant subscription receivable		—		—		—		—	—		2,287		—		—		2,287

		131,461		482,842		9,891		—	7,912		—		(113,843	)	1,260		388,062

Net loss		—		—		—		—	—		—		(147,976	)	—		(147,976	)

	2001			2000			1999
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	87,448		$	(147,976	)	$	(109,978	)
Add (deduct) items not involving cash
Depreciation and amortization		55,287			20,988			8,187
Amortization of deferred financing costs		1,580			538			698
Amortization of discount on long-term obligations		10,999			—			—
Write-down of assets		80,482			—			—
Debt conversion premiums, net of cash paid		23,574			—			—
Deferred income taxes		1,450			3,750			—
Interest paid through the issuance of common shares		1,250			—			—
Compensation cost for employee stock options		737			461			7,641
Acquired research and development		—			208,424			80,689
Extraordinary item		—			20,039			—
Cumulative effect of change in accounting principle		—			43,500			—
Equity loss		—			—			58,399
Gain on disposal of long-term investments, net		—			—			(1,948	)

		262,807			149,724			43,688
Net change in non-cash operating items		21,314			(47,230	)		8,297

Cash provided by operating activities		284,121			102,494			51,985

CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment		(44,436	)		(15,845	)		(7,759	)
Additions to intangible assets		(27,445	)		(27,752	)		(13,340	)
Proceeds on reduction in intangible assets		15,000			—			—
Disposal (acquisition) of long-term investments		(866	)		(2,454	)		11,991
Acquisitions of businesses, net of cash acquired		—			(622,145	)		(43,720	)
Maturity of (additions to) short-term investments, net		—			65,893			(54,665	)
Proceeds from sale of assets held for disposal		—			20,000			—

Cash used in investing activities		(57,747	)		(582,303	)		(107,493	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common shares, net of issue costs		589,150			109,604			253,721
Repurchase of common shares		(119,987	)		—			(30,593	)
Repayment (advance) of Executive Stock Purchase Plan loans		(9,988	)		—			3,100
Proceeds from exercise of warrants		29,093			6,010			—
Collection of warrant subscription receivable		—			2,287			4,028
Advances (repayments) under revolving term credit facility, including financing costs		(211,300	)		207,000			—
Repayment of other long-term obligations		(193,366	)		(45,602	)		(75,212	)
Issuance of Convertible Subordinated Preferred Equivalent Debentures, net of financing costs		—			288,772			—
Repurchase of U.S. Dollar Senior Notes		—			(141,017	)		—

Cash provided by financing activities		83,602			427,054			155,044

Effect of exchange rate changes on cash and cash equivalents		(229	)		(187	)		271

Net increase (decrease) in cash and cash equivalents		309,747			(52,942	)		99,807
Cash and cash equivalents, beginning of year		125,144			178,086			78,279

Cash and cash equivalents, end of year		434,891			125,144			178,086


Acquired research and development	$	137,470
Current assets		60,617
Assets held for disposal		20,000
Buildings and equipment		16,893
Intangible assets		358
Workforce		2,041
Core technology		11,185
Goodwill		30,481
Current liabilities		(21,820	)
Debt assumed		(86,071	)

Purchase price		171,154

	2001		2000
Cash and bank certificates of deposit	$	235,038	$	65,784
Money market funds and corporate debt securities		70,729		59,360
Canadian and U.S. government securities		129,124		—

		434,891		125,144

	2001		2000
Trade (net of allowance for doubtful accounts of $7,085,000 and $4,049,000 for 2001 and 2000, respectively)	$	86,325	$	98,442
Royalties		6,313		3,565
Other		3,918		3,843

		96,556		105,850

	2001		2000
Raw materials	$	12,110	$	7,140
Work in process		5,818		5,079
Finished goods		20,578		11,889

		38,506		24,108

	2001				2000
	Cost		Accumulated depreciation		Cost		Accumulated depreciation
Land	$	7,357	$	—	$	4,419	$	—
Buildings		27,154		5,116		19,489		4,553
Machinery and equipment		43,225		14,168		30,054		10,701
Other equipment and leasehold improvements		37,603		10,474		20,233		6,400

		115,339		29,758		74,195		21,654
Less accumulated depreciation		29,758				21,654

		85,581				52,541

	Options		Weighted average exercise price
	(000s)
Outstanding balance, December 31, 1998	8,841		$	6.91
Granted	3,369			18.57
Exercised	(1,334	)		5.72
Forfeited	(429	)		7.37

Outstanding balance, December 31, 1999	10,447			10.81
Granted	2,345			27.06
Exercised	(2,436	)		5.79
Forfeited	(307	)		18.29

Outstanding balance, December 31, 2000	10,049			15.58
Granted	314			43.03
Exercised	(2,906	)		9.92
Forfeited	(1,204	)		17.69

Outstanding balance, December 31, 2001	6,253			18.53

	2001		2000
Hemispherx Biopharma, Inc. (i)	$	1,285	$	1,357
Western Life Sciences Venture Fund LP (ii)		628		—
Other		442		204

		2,355		1,561

	2001		2000
Cost	$	107,321	$	109,408
Less accumulated amortization		10,844		6,303

		96,477		103,105

	2001		2000
Workforce	$	7,241	$	7,241
Core technology		11,185		11,185
Brand names, product rights and royalty interests
Cardizem®		406,070		406,070
Keftab, Dura-Vent, Rondec and Cedax		75,177		154,089
Adalat		51,459		64,720
Tiazac®		15,000		15,000
Other		33,660		22,217

		599,792		680,522
Less accumulated amortization		43,432		13,091

	$	556,360	$	667,431

	2001		2000
Accrued product returns, rebates and chargebacks	$	27,945	$	16,895
Cardizem® transitional expenses		9,725		—
Employee costs		9,708		5,696
Professional fees		3,523		2,438
Royalties		3,466		3,355
Provision for restructuring costs		1,227		3,482
Interest		2		426
Other		4,393		3,160

		59,989		35,452

	2001		2000
Up-front research and development fees	$	33,289	$	18,600
Up-front licensing and other fees		14,022		21,642
Customer prepayments		2,819		13,992

		50,130		54,234
Less current portion		27,030		26,334

		23,100		27,900

	2001		2000
Adalat obligation (i)	$	38,626	$	58,090
Deferred compensation		7,535		8,311
Revolving term credit facility (ii)		—		210,000
Cardizem® obligation (iii)		—		161,828
Non-interest bearing government loan (iv)		—		470
Other debt		—		45

		46,161		438,744
Less current portion		12,592		182,564

		33,569		256,180

Range of exercise prices	Outstanding	Weighted average remaining contractual life (years)	Weighted average exercise price		Exercisable	Weighted average exercise price
	(000s)				(000s)
$ 0.81 - 3.52⁽ⁱ⁾	221	8.0	$	3.03	73	$	3.03
5.50 - 7.75	1,784	0.9		7.70	1,760		7.71
8.75 - 12.77	852	2.0		9.39	756		9.48
17.50 - 25.00	2,173	4.9		22.13	1,999		22.10
27.72 - 40.00	979	5.9		35.32	127		35.14
41.00 - 48.13	244	4.9		44.05	38		43.61

	6,253		$	18.53	4,753	$	14.99

	2001		2000			1999
Net income (loss) as reported	$	87,448	$	(147,976	)	$	(109,978	)
Estimated stock-based compensation costs		12,216		16,680			7,534

Pro forma net income (loss)		75,252		(164,656	)		(117,512	)

Pro forma earnings (loss) per share
Basic		0.55		(1.28	)		(1.15	)
Diluted		0.50		(1.28	)		(1.15	)

	2001		2000		1999
Current	$	13,835	$	5,610	$	4,215
Deferred		1,450		3,750		—

		15,285		9,360		4,215

	2001			2000
Deferred tax assets
Tax loss carryforwards	$	40,315		$	39,837
Scientific Research and Experimental Development ("SR&ED") pool		13,881			16,664
Investment tax credits		12,802			11,180
Deferred financing and share issue costs		19,602			9,320
Plant, equipment and technology		4,547			1,123
Reserves		4,372			1,455
Intangible assets		2,889			—
Other		4,062			2,385

Total deferred tax assets		102,470			81,964
Less valuation allowance		(98,685	)		(43,250	)

Net deferred tax assets		3,785			38,714

Deferred tax liability
Intangible assets		3,785			38,714

Net deferred income taxes		—			—

	2001			2000			1999
Accounts receivable	$	4,778		$	(35,950	)	$	(9,973	)
Inventories		(14,341	)		(3,886	)		(1,560	)
Deposits and prepaid expenses		(1,296	)		(1,673	)		267
Accounts payable		1,138			(5,432	)		9,214
Accrued liabilities		24,489			(9,840	)		7,399
Income taxes payable		10,649			3,779			2,604
Deferred revenue		(4,103	)		5,772			346

		21,314			(47,230	)		8,297

	2001		2000			1999
Cardizem®	$	—	$	(239,652	)	$	—
Intelligent Polymers		—		(202,441	)		—
DJ Pharma		—		(162,802	)		—
Fuisz		—		(17,250	)		(43,720	)

		—		(622,145	)		(43,720	)

	2001			2000			1999
Issuance of common shares on surrender and redemption of Debentures	$	(314,259	)	$	—		$	—
Unrealized holding loss on long-term investments		72			893			—
Long-term obligation assumed on acquisition of Cardizem®		—			(161,828	)		—
Accrued acquisition costs related to Cardizem®		—			(4,000	)		—
Long-term obligation assumed on license of Adalat		—			(58,090	)		—
Issuance of common shares on acquisition of Fuisz		—			—			(88,243	)

		(314,187	)		(223,025	)		(88,243	)

	2001		2000		1999
Interest paid	$	22,837	$	20,546	$	14,526
Debt conversion premium paid		11,241		—		—
Income taxes paid		4,380		1,889		1,831

2001	Product Sales		Research and Development			Royalty and Licensing		Total
Revenue from external customers	$	537,138	$	14,596		$	31,529	$	583,263

Segment operating income (loss)		207,850		(47,498	)		30,900		191,252
Unallocated amounts
General and administrative expenses									(20,096	)
Interest expense, net									(33,500	)
Debt conversion premiums									(34,923	)

Income before provision for income taxes									102,733

Segment assets		733,805		44,188			19,245		797,238
Unallocated amounts
Cash and investments									406,504
Goodwill and other									127,741

									1,331,483

Segment capital expenditures, net		40,393		2,525			1,000		43,918
Unallocated amount									12,963

									56,881

Segment depreciation and amortization		41,960		3,641			2,044		47,645
Unallocated amount									9,222

									56,867

		Q1			Q2		Q3			Q4			TOTAL
2001
Product sales		$	111,927		$	125,398	$	137,147		$	162,666		$	537,138
Total revenue			119,227			133,504		152,190			178,342			583,263
Expenses			74,839			76,372		86,168			174,728			412,107
Operating income			44,388			57,132		66,022			3,614			171,156
Net income (loss)			29,166			44,103		33,101			(18,922	)		87,448
Net income excluding certain charges⁽¹⁾			29,166			44,103		55,832			73,752			202,853
EBITDA⁽²⁾			57,447			70,725		79,941			98,812			306,925
Depreciation and amortization			13,403			13,954		14,373			15,137			56,867
Diluted per share information
Net income (loss)			0.20			0.30		0.22			(0.13	)		0.58
Net income excluding certain charges⁽¹⁾			0.20			0.30		0.37			0.46			1.35
EBITDA⁽²⁾			0.39			0.48		0.52			0.62			2.04
Depreciation and amortization			0.09			0.09		0.09			0.09			0.38
Share price⁽⁴⁾
	High		47.70			45.10		48.45			57.18
	Low		29.03			29.10		37.70			44.46
2000⁽³⁾
Product sales			35,853			45,384		53,318			90,441			224,996
Total revenue			50,782			65,164		93,415			99,809			309,170
Expenses			34,737			41,936		194,862			115,667			387,202
Operating income (loss)			16,045			23,228		(101,447	)		(15,858	)		(78,032	)
Net income (loss)			(48,573	)		24,167		(100,823	)		(22,747	)		(147,976	)
Net income excluding certain charges⁽¹⁾			14,966			24,167		40,677			44,177			123,987
EBITDA⁽²⁾			21,406			27,588		44,838			57,548			151,380
Depreciation and amortization			5,540			4,478		4,908			6,600			21,526
Diluted per share information
Net income (loss)			(0.35	)		0.17		(0.78	)		(0.18	)		(1.16	)
Net income excluding certain charges⁽¹⁾			0.11			0.17		0.28			0.30			0.86
EBITDA⁽²⁾			0.15			0.19		0.31			0.39			1.05
Depreciation and amortization			0.04			0.03		0.03			0.05			0.15
Share price⁽⁴⁾
	High		35.75			28.44		42.75			45.38
	Low		19.13			19.56		27.69			31.78

HEAD OFFICE Biovail Corporation 2488 Dunwin Drive Mississauga, Ontario Canada L5L 1J9 MANUFACTURING FACILITIES Steinbach, Manitoba Carolina, Puerto Rico Dorado, Puerto Rico RESEARCH AND DEVELOPMENT FACILITIES Dublin, Ireland Toronto, Ontario Chantilly, Virginia		THE ANNUAL MEETING OF SHAREHOLDERS The annual meeting of shareholders will be held at 10:00 a.m. Tuesday, June 25, 2002 The Fairmont Royal York Alberta Room (Main Mezzanine) 100 Front Street West Toronto, Ontario M5J 1E3 STOCK EXCHANGE LISTINGS Toronto Stock Exchange (common shares only) New York Stock Exchange Trading Symbols: Common Shares: BVF Common Share Warrants: BVF.ws
SALES AND MARKETING OPERATIONS Biovail Pharmaceuticals Canada 2480 Dunwin Drive Mississauga, Ontario Canada L5L 1J9 BIOVAIL PHARMACEUTICALS INC. 170 Southport Drive Morrisville, NC 27560 AUDITORS Ernst & Young LLP Chartered Accountants Toronto, Canada LEGAL COUNSEL Stikeman, Elliott Toronto, Ontario Cahill, Gordon & Reindel New York, New York		SHARES OUTSTANDING AT DECEMBER 31, 2001 157,496,407 HOW TO REACH US FOR MORE INFORMATION For additional copies of this report, the annual report on form 20-F as filed with the United States Securities and Exchange Commission, for quarterly reports or for further information, please contact Investor Relations. By Mail: Biovail Corporation 2488 Dunwin Drive Mississauga, Ontario Canada L5L 1J9 By phone: (416) 285-6000 By fax: (416) 285-6499 By e-mail: ir@biovail.com By web: www.biovail.com
REGISTRARS AND TRANSFER AGENTS CIBC Mellon Trust Company Toronto, Canada Mellon Investor Services LLC New York, New York		The following words and logos are trademarks of the Company and may be registered in Canada, the United States and certain other jurisdictions: Biovail, Cardizem®, Tiazac®, Viazem, CEFORM®, Shearform®, FlashDose® and Cardisense®.